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and	 therapeutics.	Their	high	specificity	 in	 recognition	 is	 the	main	 factor	why	antibodies	are	
most	 sought	 after.	 Periodically,	 the	first	 antibodies	 prepared	were	 of	 animal	 origin	 by	Emil	
Behring	and	Shibasabura	Kitasato	against	diphtheria	toxin	[1].	Since	then,	with	major	advances	




in	 the	blood	or	other	bodily	fluids	of	vertebrates.	They	are	hugely	attributed	 to	 the	humoral	
immune	system	and	is	an	essential	product	of	the	adaptive	immune	system.	The	production	of	
antibodies	is	accredited	to	a	type	of	white	blood	cell	called	B-cell.	When	an	antigen	is	presented	









polypeptide	 chains	 held	 together	 by	 inter-chain	 disulphide	 bridges.	The	 two	 halves	 contain	
a	 heavy	 and	 a	 light	 chain.	 Each	 chain	 is	made	 up	 of	 different	 structural	 domains	 called	 Ig	
domains.	The	domains	are	called	 the	variable	 (IgV)	domain	and	 the	constant	 (IgC)	domain.	
























to	 them,	 stimulate	 the	 removal	 of	 pathogens	 by	 recruiting	macrophages	 and	 prompt	 direct	
termination	of	pathogens	via	complement	activation		[2,3].	
3	 The	Fc	region	of	the	antibodies	is	responsible	for	complement	activation	via	attachment	
of	 the	first	 component	of	 the	 complement	 cascade	 thus	 activating	 the	 classical	 complement	
system.	This	enables	 the	assassination	of	bacteria	 in	 two	processes.	First	 is	a	process	called	






























to	 introduce	 regions	 of	 high	 diversity	 (CDR	 regions)	 and	 regions	where	 the	 sequences	 are	
conserved	 (framework	 regions).	 This	 somatic	 recombination	 process	 is	 called	 the	 V(D)J	
recombination	(Figure	1.2)	[12,13].
	 V(D)J	 recombination	accounts	 for	 the	generation	of	 the	primary	antibody	repertoire.	


















































































magic	 bullet	 was	 discovered	 in	 1975	 when	 Kohler	 and	 Milstein	 realised	 Ehrlich’s	 vision	
with	the	introduction	of	monoclonal	antibodies	[23].	A	continuous	culture	of	antibodies	with	
predefined	specificity	was	able	to	be	produced.	This	paved	the	way	to	many	daughter	methods	







	 MAb	production	 involves	 the	 fusion	of	myeloma	cells	with	 spleen	cells	of	 a	mouse	
that	has	been	immunized	with	an	antigen.	The	cells	are	fused	together	 to	form	a	hybridoma	
using	polyethylene	glycol.	Taking	advantage	of	 the	 inability	of	myleoma	cells	 to	synthesize	









9Figure 1.4: Conventional murine monoclonal antibody technology and daughter methods for 
the	recombinant	production	of	monoclonal	antibodies.	
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	 To	circumvent	 this	problem,	Jones	et al. in	1986	experimented	on	 the	CDR	grafting	










































genotype	 information	 with	 phenotype	 interaction,	 the	 	 interaction	 between	 the	 synthesized	
polypeptide	to	the	ribosomal	complex	must	be	maintained.	Dissociation	of	this	complex	occurs	
in	ribosome	display	thus	resulting		in	the	lost	of	genotype	and	phenotype	coupling.














antibody	 library	 sizes	 [65,67].	Another	 problem	worth	 noting	 is	 	 the	 loss	 of	 activity	 of	 the	
selected	antibody	format	after	expression	in	soluble	form.	This	was	reported	with	the	selection	
of	mammalian	 calmodulin	 (CaM)	protein.	The	 investigators	 reported	 the	 possbility	 that	 the	
Aga-2	fusion	contributes	to	the	binding	observed	thus		loosing	the	binding	characteristics	when	
expressed	without	the	Aga-2	fusion	[68].








	 With	 the	 introduction	of	 phage	display,	 it	was	 then	possible	 to	 engineer	 natural	 and	
synthetic	 antibody	 fragments	 for	 screening.	The	first	 antibody	 format	 to	 be	 generated	 from	









Figure 1.5 : The various types of antibody formats available for use or modification. The	 modular	
domain	 architecture	 of	 immunoglobulins	 has	 been	 exploited	 to	 create	 a	 growing	 range	 of	 alternative	
antibody	 formats	 that	 spans	 a	 molecular-weight	 range	 of	 at	 least	 12–150	 kDa	 and	 a	 valency	 (n)	 range	






are	being	used.	Bi-scFv,	 triabody,	diabody,	minibody	and	 tetrabody	are	 some	of	 the	models	


























	 Several	 factors	 should	 be	 considered	 when	 designing	 Fab	 phagemid	 vectors.	 The	




First	 is	 the	 balanced	 expression	 of	 both	 antibody	 chains	 as	 either	 light	 or	 heavy	 chain	 can	
be	fused	to	pIII.	The	use	of	a	phagemid	vector	allows	the	down	regulation	of	expression	by	
glucose	using	the	lacZ	promoter.	It	can	also	allow	control	of	the	amount	of	antibody-pIII	fusion	

























library.	 In	phage	display,	 libraries	of	 remarkably	 large	 sizes	 (1010)	 have	been	 reported	 [92].	
The	 assumption	 is	 that	 the	 affinities	 of	 the	 antibodies	 are	 proportionate	 to	 the	 size	 of	 the	
libraries	[93].	A	clear	distinction	between	the	terms	antibody	library	source	and	format	is	vital	
to	understanding	 the	concept	of	 recombinant	human	antibody	production.	Antibody	 sources	
can	be	categorized	to	two	main	classes	based	on	the	origin	of	antibody	sequences	being	either	
natural	or	synthetic	repertoires	(Figure	1.6).	Natural	source	repertoire	 libraries	are	generally	
either	 naïve	 or	 immunized	 libraries	 [92,94,95].	 Synthetic	 source	 repertoires	 are	 constructed	
entirely	in	vitro	and	is	devoid	of	natural	biases	and	redundancies	of	in	vivo	antibody	repertoires	
which	allows	the	control	of	genetic	information	and	introduce	diversity	[95,96,97].






Table 1.1: Various types of helper phage available [91].
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	 An	immunized	library,	as	 the	name	would	suggest,	derives	 the	antibody	cDNA	from	
patients	that	had	prior	exposure	to	a	certain	disease	or	infection	and	recovered.	Here	the	natural	
antibodies	which	have	 reacted	 towards	 the	 infection	 are	harvested	 from	 the	B-cells.	The	 Ig	
isotypes	 normally	 used	 for	 library	 generation	 is	 IgG	 [105]	 but	 other	 isotype	 libraries	 like	
IgA	and	IgE	have	been	generated	with	reference	to	specific	diseases	such	as	coeliac	disease	
[106,107]	 and	 latex	 allergic	 [108]	 patients	 respectively.	 Therefore	 the	 possibility	 to	 obtain	
antibodies	against	these	antigens	is	higher	as	it	is	biased	towards	the	given	antigen.	The	size	

























of	 the	V-genes	 is	 required.	When	 randomization	 of	 CDRs	 	 are	 carried	 out	 to	 increase	 the	
affinities	of	antibodies	from	naïve	libraries,	the	resulting	library	would	have	a	single	framework	
with	variations	only	in	 the	CDRs.	This	 library	is	called	a	semi-synthetic	 library	as	 the	main	
framework	was	 derived	 from	 a	 naïve	 library	 subsequently	modified	 in	 vitro	 to	 yield	 better	
antibodies	[116,117,118].


















synthetically	 [138,139,140].The	 different	 binding	 structures	 of	 antibodies	 correlates	 to	 the	
diversity	due	to	the	folds	genereated	by	varying	amino	acid	sequences	of	both	chains	[141,142].	
Work	on	 light	 and	heavy	chain	 interactions	have	also	assisted	designers	 in	designing	better	
antibody	 stuctures	 [143,144,145].	Coupled	with	 the	 innovations	 in	mutagenesis	 technology,	





	 The	 obvious	 advantage	 of	 such	 libraries	 is	 the	 independence	 from	 natural	 immune	















	 The	main	ingredient	 to	ensure	 	successful	selection	of	useful	antibodies	 is	a	primary	
phage	library	of		high	quality.	Criterion	for	high	quality	would		constitute	a	large	functional	
size	with	a	high	antibody	sequence	diversity.	This	is	to	facilitate	the	selection	of	high	affinity	














	 In	phage	display	 the	panning	 is	an	 iterative	process	where	specific	binder	molecules	
are	continuously	enriched	and	multiplied	from	a	pool	of	predominantly	non-binders	until	the	


















out	 before	 starting	 the	 selection	 process	 depending	on	 the	 type	 of	molecules	 presented	 and	
binding	characteristics	of	 the	binder	and	 target.	Careful	considerations	 should	be	 taken	 into	





Figure	 1.7:	 Phage	 display	 panning	 process	with	 timeline	with	 4	 panning	 rounds.	 Phage	 life	 cycle	 in	E. 
Coli	highlighted	in	box.	The	drawing	is	schematic	and	not	to	scale.	(1)	Phage	bind	to	the	E. coli	cell	through	
the	 pIII	 coat	 protein.The	 single-stranded	 viral	 genome	 (C	 strand,	 single	 circle)	 is	 injected	 into	 the	 cell	 and	 a	
complementary	 strand	 (K	 strand)	 is	 synthesized	 to	 form	 a	 double-stranded	 phage	 genome	 (double	 circle).	 (2)	
Subsequently,	 all	 ten	phage-encoded	proteins	 are	 produced	by	host-mediated	protein	 synthesis,	 including	 coat	
proteins	 (pIII,	 pVI,	 pVII,	 pVIII	 and	 pIX),	 Proteins	 for	 replication	 (pII,	 pV	 and	 pX)	 and	 proteins	 involved	 in	
assembly	 and	 export	 (pI	 and	 pIV).	 (3)	The	 phage	 genome	 is	 replicated	 using	 the	 (C)-strand	 as	 a	 primer	 and	




































or	absent	expression	of	 the	sequence	 in	E. coli.	An	approach	 to	overcome	this	bottleneck	is	
to	have	codon	based	mutagenesis	of	clones	in	vitro.	Expression	levels	can	be	predicted	using	
codon	bias	 thus	allowing	 improvements	of	expression	 levels	 [162,163].	Codon	optimization	
has	 been	 shown	 to	 increase	 expression	 of	 recombinant	 proteins	 [164,165].	 Proper	 handling	































	 The	 immune	 repertoire	 generation	 would	 require	 designing	 a	 collection	 of	 V-
gene	 primers	 with	 a	 high	 coverage	 of	 the	 natural	 immune	 repertoire	 present	 in	 the	
immune	 system.	 V-gene	 primers	 based	 on	 the	 best	 format	 would	 be	 designed	 and	
evaluated.	 An	 optimized	 protocol	 is	 also	 required	 to	 ensure	 the	 utmost	 amplification	
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     pH 7.4. Dissolve 8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4		
     and 0.24 g KH2PO4 in 800 mL of ddH2O. Adjust the pH  
     to 7.4 with HCl. Add ddH2O to 1 L.
4 % BSA    4 g BSA in 100 mL PBS.
Software Manufacturer




GraphPad Prism 5 GraphPad	Software	Inc,	USA
Vector NTI Suite 10.0 Invitrogen GmbH, Karlsruhe, Germany
Microsoft Excel 2003 Microsoft Co, USA
Microsoft Word 2003
EndNote 10.0 Niles	Software	Inc.,	USA
Ascent Thermo Scientific, Oberhausen, Germany
Apparatus Manufacturer
General Laboratory Equipments
Autoklav Typ 23 Melag GmbH, Berlin, Germany
Weighing machine Adventure Pro AV812 Ohaus, USA
MTP spectrophotometer, SpectraMAX 250 Molecular Devices, Sunnyvale, CA, USA
Freezer, -80ºC Forma Thermo Scientific, Oberhausen, Germany
Microflow Laminar Flow Workstation
NanoDrop ND-1000
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4 % Milk Powder   4 g dry milk powder in 100 mL PBS.
10 x HMFM (freezing mix)  Dissolve 72 g KH2PO4 and 188 g K2HPO4 in 800 mL  
	 	 	 	 	 ddH2O and autoclave. Dissolve 3.6 g MgSO4.7H2O,  
     18 g Na
3
-citrate.2H2O, 36 g (NH4)2SO4 and 1,760 g   
     glycerol (1,645 ml of 87% glycerol) in 3.2 L ddH2O,  
     autoclave and add 800 ml of the phosphate solution. 
40 % (w/v) glucose   400 g D-+-glucose monohydrate dissolved in ddH2O to  
     1 L and sterilised by filtration through a 0.2 μm pore size 
     filter.
70 % (v/v) Ethanol    700 mL of technical grade Ethanol dissolved in ddH2O  
     to 1 L.
1 M IPTG     1.19 g of Isopropyl-b,D-thiogalactoside in 5 mL ddH2O.  
	 	 	 	 	 Store	at		-20°C.
0.5 M EDTA, pH 8.0   Dissolve 186.1g Na2EDTA·2H2O in 800 mL ddH2O.  
     Adjust pH to 8.0 with NaOH (~20g of NaOH pellets).  
     Adjust volume to 1 L with ddH2O.
8 M Urea     Dissolve 48 g of Urea in 100 mL of ddH2O.
20% PEG 6000/ 2.5 M NaCl   Dissolve 200g of PEG 6000 and 146 g of NaCl to 1 L  
	 	 	 	 	 with	ddH2O.
7.5 M Ammonium acetate, pH 7.5  Dissolve 57.8 g ammonium acetate in approximately  
     50 mL ddH2O. Adjust pH to 7.5 with ammonium   
     hydroxide. Adjust to final volume of 100 mL.
1 M NiSO
4
.6H2O   Dissolve 264 g of NiSO4.6H2O in 1 L of ddH2O.
100 % Ethanol
1 M Tris-HCl (pH 6.8)  Dissolve 12.1 g Tris base in 50 mL of ddH2O. Adjust pH  
	 	 	 	 	 with	concentrated	HCl	and	add	ddH2O to a final volume  
     of 100 mL.
1 M DTT     Dissolve 770 mg Dithiothreitol in 10 mL ddH2O. Store  
	 	 	 	 	 at	-20°C.
GlycoBlue from Applied Biosystems, USA.
UltraPure Agarose, Invitrogen GmbH, Karlsruhe, Germany
Biocoll from Biochrom AG, Berlin, Germany.
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SDS-PAGE Buffers
4 x SDS loading buffer  0.4 % bromophenol blue, 50 % (w/v) glycerol, 8 %   
     SDS, 0.4 M DTT and 0.2 M Tris-HCl pH 6.8. To   
     prepare 7.5 mL of buffer, dissolve 1.5 mL of 1 M Tris- 
     HCl (pH 6.8), 3 mL of 1 M DTT, 0.6 g of SDS powder,  
     0.03 g of bromophenol blue and 3 ml of 100% glycerol.
Coomassie blue staining solution  Dissolve 1.25 g Coomassie Brillant Blue G 250 in 225  
     mL technical grade ethanol, 225 mL ddH2O and 50 mL  
     acetic acid were added. The mixture was stirred for 2  
     hr and filtered through a folded filter paper.
Destain solution    20 mL of ethanol and and 10 mL of  acetic acid in a final  
     volume of 100 mL with ddH2O. 
20x MES buffer    Dissolve 195.2 g of MES, 121.2 g of Tris Base, 20 g of  
     SDS and 6 g of EDTA in 800 mL of ddH2O. Adjust the  
     pH to 7.3 and add ddH2O to a final volume of 1 L. The  
     final concentration would be 1 M MES, 1 M Tris Base,  
     69.3 mM SDS, 20.5 mM EDTA, pH 7.3. 
Western Blot and ELISA Buffers
Transfer buffer    Dissolve 4.2 g of Tris Base with 19.6 g of Glycine in   
	 	 	 	 	 ddH2O to a final volume of 1.4 L.   
Blocking and dilution buffer (PTM) Dissolve 2 g of Milkpowder and 1 mL (v/v) Tween 20 to  
     100 mL of PBS.
Wash buffer (PBS-T)   Dissolve 1 mL (v/v) Tween 20 in 1 L of PBS
Citrate buffer    10 mL of 50 mM Tri-natrium citrate with 10 mL of 50  
     mM citric acid
Development substrate  1 ABTS tablet with citrate buffer and 10  µL of 
hydrogen     peroxide.
Gel Electrophoresis Buffers
Running buffer (10x TBE)  Dissolve 1 g NaOH, 108 g Tris Base, 55 g Boric Acid  
     and 7.4 g EDTA 700 mL ddH2O in 2 L flask with   




31 g premixed 2YT-Broth (16 g tryptone, 10 g yeast extract, 5 g NaCl) was dissolved in dH2O to 
1 L, sterilised by autoclaving at 120ºC for 20 min and cooled toRT. Prior to use, the appropriate 
amounts of antibiotics, glucose and IPTG was added.
2YT-Broth Agar
46 g premixed 2YT-Broth Agar (16 g tryptone, 10 g yeast extract, 5 g NaCl, 15 g agar) was 
dissolved in dH2O to 1 L, sterilised by autoclaving at 120ºC for 20 min and cooled to 55°C 
in a waterbath. Agar medium was supplemented with appropriate amounts of antibiotics and 
glucose and poured into 90 mm diameter Petri dishes under a laminar flow. After solidification 
agar plates were packaged in plastic bags and stored at 4°C in a dark place until use, but for a 
maximal period of 20 days.
Top Agar
Dilute 100 mL of heated 2YT-Broth Agar with 100 mL of 2YT-Broth.
SOB Media
20 g of Tryptone, 5 g of yeast extract and 0.5 g of NaCl was dissolved in ddH2O to 1 L, sterilised 
by autoclaving at 120°C for 20 min and cooled to rt. 
SOC Media
For 100 mL of SOC media, 1 mL of 40% glucose, 1 mL of 1 M MgCl2 and 1 mL of 1 M MgSO4 
was made up to 100 mL using SOB media.   
3.6	 Additives
Ampicilin :- Stock: 50mg/mL in 50% EtOH;  Working concentration: 100µg/mL
Chloramphenicol :- Stock: 34mg/mL in ddH2O; Working concentration: 17µg/mL
Kanamycin :- Stock: 30 mg/mL in ddH2O ; Working concentration: 60 µg/mL
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3.7	 Microorganisms	and	Eukaryotic	cell	lines
DB3.1   F- gyrA462 endA1 glnV44 Δ(sr1-recA) mcrB mrr hsdS20(rB-, mB-	 ) 
   ara14galK2 lacY1 proA2 rpsL20(Smr) xyl5 Δleu mtl1- from Invitrogen  
   GmbH, Karlsruhe, Germany.
DH10B  F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 endA1  
   araD139Δ(ara, leu)7697 galU galK λ- rpsL nupG - from Invitrogen  
   GmbH, Karlsruhe, Germany.
TG1   supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK–	mK–) [F´ traD36   
   proAB  lacIqZΔM15]-  from Stratagene, Agilent	Technologies,	USA.
HB2151  nalr thi-1 ara ( (lac-proAB [F’ proAB+ laciq lacZ(M15] - from   
	 	 	 Stratagene,	Agilent	Technologies,	USA.
BL21 Star™(DE3)  F– ompT hsdSB(rB–, mB–) gal dcm rne131 (DE3) - from Invitrogen  
   GmbH, Karlsruhe, Germany.
Helper phage M13-K07 - from New England Biolabs, Frankfurt, Germany.
Hyperphage is courtesy of Prof Stephan Dübel, TU-Braunschweig.
3.8	 Plasmids
pRSET-BH6 was used as for the recombinant expression of in vivo biotinylated target antigens. 
pRSET-BH6-GW was used for cloning full length proteins by gateway recombination.
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pSABA courtesy of Dr Bass was used as for the generation of the pTSL phagemid vector 
series.
pRARE3 courtesy of Dr Langer was used as a helper plasmid for the expression of recombinant 
proteins.
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pHAL-D1.3 was used as for the generation of the pTSL phagemid vector series.
pCR4-TOPO was used as for the generation of the pTSL phagemid vector series.
pUC18 was used as for the generation of the pTSL phagemid vector series.
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3.9	 Recombinant	Proteins,	Affinity	Columns	and	Magnetic	Beads
Biotinylated Protein L, Invitrogen GmbH, Karlsruhe, Germany
Protein L-HRP conjugated, Invitrogen GmbH, Karlsruhe, Germany
Streptavidin-HRP, Thermo Scientific, Oberhausen, Germany
Ni-NTA agarose beads, Qiagen GmbH, Hilden, Germany
Protino Ni-TED silica beads, Macherey-Nagel GmbH & Co. KG, Düren, Germany 
MonoAvidin beads, Thermo Scientific, Oberhausen, Germany 
Dynabeads® M-280 Streptavidin, Invitrogen GmbH, Karlsruhe, Germany
3.10	 Antibodies
Anti-M13-HRP, mouse mAb, GE Healthcare, Munich, Germany	
Anti-Mouse IgG-HRP, rabbit Sigma-Aldrich Chemie GmbH, Munich, Germany 
Anti-Penta•His antibody, mouse mAb Qiagen GmbH, Hilden, Germany
3.11	 DNA	and	Protein	Markers
DNA markers from Fermentas GmbH, St. Leon-Rot, Germany
GeneRuler 1 Kb Plus, GeneRuler 100 bp Plus, 
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MagicMark XP Western Protein Standard, Invitrogen GmbH, Karlsruhe, Germany
Pre-stained precision protein marker Bio-Rad Laboratories GmbH, München, Germany
Kit Name Manufacturer
PAGE	Blue	stain Fermentas GmbH, St. Leon-Rot, Germany
Protino®	Ni-TED	Resin MACHEREY-NAGEL GmbH & Co. KG, 
Düren, Germany
SERVA Silver Stain Kit SERVA Electrophoresis GmbH, Heidelberg, 
Germany
Pierce 660 nm Protein Assay Thermo Scientific, Oberhausen, Germany
Protein L Fast Flow Column
Monomeric Avidin Kit
RNeasy Kit Qiagen GmbH, Hilden, Germany
QIAprep Spin Miniprep Kit
QIAGEN Plasmid Maxi Kit
QIAquick PCR Purification Kit
















Bio	X	Act	Short BioLine, Luckenwalde, Germany
High Fidelity PCR Enzyme Mix Fermentas GmbH, St. Leon-Rot, Germany
recombinant Taq Polymerase (House Taq) Max Planck Institute For Molecular Genetics
Phusion Hot Start Polymerase New England Biolabs, Frankfurt, Germany
REDTaq Sigma-Aldrich Chemie GmbH, Munich, 
Germany
Ligase
T4 DNA Ligase New England Biolabs, Frankfurt, Germany
T4 DNA Ligase Promega GmbH, Mannheim, Germany
Phosphatase
Antartic	Phosphatase New England Biolabs, Frankfurt, Germany
Reverse Transcriptase
SuperScript®	II Invitrogen GmbH, Karlsruhe, Germany
totalscript-OLS® Omni Life Science, Hamburg, Germany
Other Materials






 All oligonucleotides were ordered from Invitrogen GmbH, Karlsruhe, Germany with a 












IgD CH1 MluI Rv GCCTCCACGCGTAGATTCTGGCCAGCGGAA-
GATCTCCTTCTTACTCTTGCTG
IgD CH1 XhoI Fw CTCGAGCCCAACCAAAGCAGATGTGTTTCCAATCAT-
ATCAGGGTGCA
IgG CH1 MluI Rv GCCTCCACGCGTGCAAGATTTGGGCTCAACTTTCTT-
GTCCACCTTGGTGTTGC












Random Primers New England Biolabs, Frankfurt, Germany
10 mM dNTP mix
S1 Nuclease Roboklon GmbH, Berlin, Germany





























 The semi-synthetic antibody repertoires used were of human origin and were cloned into 
phagemid vectors. The antibody fragments are displayed as single–chain variable Fragments 
(scFv). These library is courtesy of Dr. Ian M. Tomlinson and Dr. Greg Winter, MRC – Centre 
of Protein Engineering, Cambridge, UK. The randomised (DVT) positions in the side chains 
are based mainly on those positions which are diverse in the primary – germline – repertoire 
(total of 18 residues – H50, H52, H52a, H53, H55, H56, H58, H95, H96, H97, H98, L50, L53, 
L91, L92, L93, L94 and L96). 96% of the clones tested contain an insert and the library size is 
estimated to contain~ 1.5 x 108 primary clones.
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3.16	 Magnetic	Particle	Processor
 The Magnetic Particle Processor (Figure 2.1) was used to conduct the washing and in-
cubation of magnetic particles. It is a prototype instrument of the KingFisher magnetic particle 
processor	series	of	Thermo Scientific. It enables the handling of 96 magnetic pins, corresponding 
to the positions of a 96-well microtitre plate (MTP). The MPP has three predefined positions for 
96-well plates and can accommodate three MTP’s filled with the individual buffers for each wash 
or incubation step respectively. The magnetic particles are transferred between wells by a capture 
and release motion using the rod-shaped magnets covered with plastic caps. The modular system 
of the MPP allows the use of any number of 8-magnet columns between one and twelve. Each in-
dividual column position (1-12) on a MTP can be independently programmed. Instrument control 
is dependent on the Ascent software provided, and parameters such as time, position, frequency 
and strength of shaking movements is user-defined. Therefore, the MPP allows reproducible 
control of each step of the phage display selection protocol for as many as 96 parallel selections.
Figure	2.1:	Magnetic	particle	processor. Left: rod-shaped magnets and plastic caps separated, magnetic 
particles in solution in microtitre plate wells. top right: magnets in plastic caps, collection of magnetic 















	 For	 the	 evaluation	of	 the	 correct	 cell	 density	 to	make	 a	 suitable	 dilution,	 all	 optical	
densities	have	been	measured	at	a	wavelength	of	OD600	against	a	blank	value	(media).
4.1.4	 Preparation	of	electrocompetent	cells
	 For	 the	 production	 of	 electro	 competent	E.	 coli	 cells	 (strain	DH10B,	TG1,	HB2151	
and DB3.1) 50 mL 2YT medium in a 250 mL Erlenmeyer flask were inoculated with bacteria 
culture	from	glycerol	stock	and	grown	o/n	at	37°C.	On	the	following	day	500	mL	of	preheated	
2YT medium in a 2 L Erlenmeyer flask were inoculated with bacterial o/n culture and grown at 
37°C	until	OD600	0.25-0.50	was	reached.	The	culture	was	chilled	on	ice	for	30	min,	separated	
to	4	pre	chilled	250	mL	bottles	and	 then	centrifuged	 for	15	min	at	4°C	and	4000	 rpm.	The	
cell	pellet	was	resuspended	in	125	mL	ice-cold	Millipore	water	and	kept	on	ice	for	15	min.	
Another	centrifugation	step	was	done	as	before.	The	pellet	was	resuspended	in	50	mL	ice-cold	
Millipore	water,	 transferred	 to	50	mL	Falcon	 tubes	and	kept	on	 ice	again	 for	15	min.	After	
another	centrifugation	step	the	pellet	was	resuspended	in	25mL	ice-cold	10%	glycerol	and	kept	
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	 When	5	mL	of	E. coli culture were purified to isolate the plasmid – DNA the “QIAprep 
Spin Miniprep” Kit of QIAGEN was used. In the purification of 100-200 mL bacteria culture the 
“Plasmid Maxi Kit” of QIAGEN was used. The purifications were done to the manufacturer’s 
specifications.  
4.1.6	 Gel	electrophoresis	separation	of	DNA
 The agarose gel electrophoresis is a method for size dependent separation of DNA. At 
first an agarose gel (0.7-1.2 % in 0.5x TBE) with ethidium bromide (1 % v/v) was prepared. The 
DNA was mixed with loading buffer and loaded into small pockets of the gel. The separation 
was done in an electrical field with 80-120 V and 150-400 mA. For the documentation and 
visualization of DNA – fragments the ‘Gel Doc 2000’ station (BioRad) was used. 
4.1.7		 DNA	extraction	from	gel	electrophoresis
 The extraction of DNA-fragments out of an agarose gel was carried out with the 
‘QIAquick Gel Extraction’ Kit of QIAGEN and to the manufacturer’s specifications.
4.1.8	 DNA	concentration	with	Ethanol	precipitation







 1.5 µL of DNA was used for concentration determination using the NanoDrop ND1000. 
Duplicate	readings	are	taken	and	the	concentration	is	calculated	as	the	average	of	the	readings.
The determinations were done to the manufacturer’s specifications.  
4.1.10	 Restriction	enyzme	digestion
 Restriction endonucleases cuts plasmid DNA at specific sequences. All restriction 
enzymes were used from NEB with the supplied buffers. Digestions were done using 100 to 
1000 ng of DNA with sufficient units of enzyme as recommended by the supplier. Double 
digestions are carried out using the best buffer conditions according to the manufacturer’s 
sepcification. All digestions are incubated at 37°C o/n unless stated otherwise.
4.1.11		Dephosphorylation	of	digested	plasmids
	 To	avoid	a	 religation	of	 the	digested	plasmid,	 the	vector	was	dephosphorylated	with	
Antarctic Phosphatase (NEB).  For this purpose 1/10 volume of 10x Antarctic Phosphatase 
buffer and 1 µL of Antarctic Phosphatase (5 Units) were added to 1 µg of digested DNA. The 
mixture was incubated for 15 min at 37°C in the case of 5’extensions or blunt-ends or 60 min 




 Ligation of two DNA fragments are carried out to combine the sequences together 
using T4 DNA Ligase. The amount of digested vector varies from 100-1000 ng. The applied 





with T4-DNA-ligase in ddH2O. The end volume was conformed to the DNA-concentrations. 
The	ligation	was	carried	out	o/n	at	15°C.
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4.1.13	 Transformation	of	E. coli by	electroporation
 For the transformation, 1µL of the DNA was transferred to 50 µL of ice-thawed 
electro	competent	cells.	The	mixture	was	pipetted	to	an	ice-cold	electroporation	cuvette	with	
a 1 mm electrode gap. The electroporation was performed at 1.5kV for 5 ms. Directly after 
the electroporation, 1 mL of SOC media at RT was added to the mixture. The mixture was 
then	incubated	for	1	hr	at	37°C	and	120	rpm	for	bacteria	regeneration.	Bacteria	was	pelleted	
by	centrifugation	for	4	min	at	full	speed.	The	cell	pellet	was	resuspended	in	100	µL	of	SOC	




 For sequencing, at least 250 ng of plasmid DNA and 20 µL of each primer (10µM) was 
given	to	 the	 in-house	service	department	of	 the	 institute,	where	sequencing	was	carried	out.	
Sequencing	traces	were	obtained	electronically	and	analysed	using	Contig	Express	software	of	
the VectorNTI software package.  
4.1.15		PCR	protocols
 The polymerase chain reaction is a technique employing DNA-polymerase to amplify 
DNA to several orders of magnitude from the initial copy in a doubling process. A conventional 
PCR cycle can be divided into three steps:
1. Denaturation: double stranded DNA is dissociated to single stranded DNA at high  
	 temperatures	(94-98°C).
2. Annealing: sequence-specific oligonucleotides (primer) complementing single-strands. 
	 are	introduced.	The	annealing	temperature	is	about	3-5°C	lower	than	the	melting	point		
	 of	the	primers	(normally	50-65°C).	A	primer-template	hybrid	is	then	formed.	
3. Elongation: the mechanism of building a new strand of DNA from 5’to 3’ with the  
 help of the polymerase and excess dNTPs at 72°C. 
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 The steps from 1 to 3 are usually repeated for 25 to 30 cycles. At the end of the PCR 
a primer-flanked DNA region is multiplied countless times. For preparative amplification of 
DNA-fragments the polymerases Bio X Act Short, REDTaq and Phusion Hot Start were used 
for fragments up to 1 Kb in length. The High Fidelity PCR Enzyme Mix was used for fragments 
3	Kb	 in	 length.	For	 analytical	 purposes	 the	House-Taq	was	used.	All	 polymerases	 are	used	
together	with	the	supplied	reaction	buffer.	Additives	such	as	MgCl2	and	DMSO	were	applied,	if	
necessary. The DNA amount differed from 20-50 ng. The concentration of the dNTP-mix was 




 This was carried out to amplify DNA material for downstream experiments. 1 µL of 




 This process was conducted to identify optimal conditions for PCR amplification of 
certain DNA fragments. A set of 8 different temperature settings are used for temperature 





 Two individual PCR fragments were digested with appropriate restriction enzymes 
and purified using the Qiagen PCR Purification Kit to remove excess enzyme and short DNA 
fragments,	and	for	buffer	exchange	to	ddH2O or elution buffer (TE buffer). The purified ligated 












 Analytical PCR was used to analyze clones or plasmid preparations for the integration 
of specific DNA sequences into the vector backbone. Specific primers that anneal to the vector 
backbone are used. All analytical PCR experiments were carried out using the HouseTaq in a 
volume	of	20	µL.
 PCR reactions used are based on the following conditions highlighted in Table 4.1. 
Depending on the varying constructs and application purposes, modifications to the temperature 
settings	and	time	are	based	on	the	optimization	process.	Table	4.2	shows	the	conditions	for	a	




dNTP mix 2.5	mM 1.6
Polymerase Manufacturer’s recomendations x
Buffer Dilute	to	recomendation y
Forward Primer 0.1	µM 0.4










e Repeat steps b - d 30	times
f 72 5:00
Table	4.2:	Typical	PCR	program.
f. Addition of additives to PCR experiments.
 - MgCl2	concentration	optimization	to	PCR	amplifications.	
	 	 MgCl2	concentration	for	polymerase	optimization	was	performed	by	increasing	
 each manufacturer’s recommended MgCl2	concentrations	by	0.25	mM,	0.5	mM		 	
 and 1.0 mM (final conc.), respectively. The manufacturer’s recommendations are as  
 follows: REDTaq 1.1 mM, BIO-X-ACT 1.0 mM, and Phusion 1.5 mM.
	 -	 Addition	of	ETSSB	to	PCR	amplifications.
  Where applied, 0.2 µL of ET SSB (500 µg/mL) from New England Biolabs  
 (Frankfurt, Germany) was added to each 20 µL PCR reaction. Supplied reaction   
 buffers were added according to manufacturer’s information. 
g. Semi-quantitative analysis of PCR performance.
	
 Gels were photographed using a gel documentation station (Gel Doc 2000, Bio-Rad, 
Munich, Germany) and specific amplification bands were quantified using AIDA® image 
analyzer software 4.10 (Raytest, Straubenhardt, Germany). All gel images were analyzed using 
the 1D evaluation tool with a fixed lane width of 18 pixels. The band intensities were normalised 





insert using T4 DNA ligase (4 U/µL) from Promega in a 50 µL reaction volume. Ligation was 
carried	out	o/n	at	8°C.	The	ligation	product	was	subjected	to	ethanol	precipitation	and	reconstituted	






 Before proceeding to reverse transcription (RT) 1 µg of RNA per sample was treated 
with DNase (Sigma-Aldrich, Munich, Germany) for 15 min at rt followed by heat inactivation of 
the DNase at 70°C for 10 min. Using always the same batch of total RNA, two different RTases 
were evaluated in parallel; SuperScript® II (Invitrogen, Karlsruhe, Germany) and totalscript-
OLS® (Omni Life Science, Hamburg, Germany). Total cDNA preparation was performed using 
oligo(dT)12-18	 primer	 and	 random	primers	 together	 (Invitrogen,	Karlsruhe,	Germany).	 For	
gene specific amplification, gene specific primers were used. All RT reactions were carried out 
according to the manufacturer’s recommendation containing equal amounts of total RNA (400 
ng)	as	starting	material.	
4.1.18	 PBMC	preparation	and	RNA	isolation
 Peripheral blood mononuclear cells (PBMCs) were separated from peripheral blood of 





tube. Sterile PBS was added up to a final volume of 50 mL and cells were centrifuged for 10 
min at 1200 rpm (. The supernatant was discarded and the cell pellet was resuspended in RTL 
buffer
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for RNA isolation using the RNeasy kit from Qiagen (Hilden, Germany). RNA isolation was 
according to the supplied protocol. The RNA quality and concentration was determined using 
a RNA 6000 NanoChip® with an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany). 
From	all	individuals	included	in	this	study	informed	consent	was	obtained.
4.1.19	 Evaluation	of	RNA	samples
a.  Pre-analysis preparations.





 4. Gel matrix preparation:- 550 uL of gel matrix was added to a spin filter and  
 centrifuged for 10 min at 4000 rpm  (1500g). 65 uL filtered gel was transfered   




 new 0.5 mL RNase free microfuge tubes. The matrix was vortexed thoroughly for 10  
	 sec.	The	gel-dye	matrix	was	centrifuge	at	maximum	speed	(14000	rpm)	for	10	min.		
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b.  RNA sample analysis.
 A new RNA6000 Nanochip was placed on the priming station. 9 uL of gel-dye matrix 





5 uL of RNA marker was added into the well marked ladder and each of the 12 RNA wells. 
6 uL of the marker must be loaded into each unused well. RNA sample and RNA ladder was 
incubated at 70° C for 2 min and placed on ice for 5 min. Sample and ladder was briefly spun 
to concentrate solutions to the bottom. 1 uL of ladder was loaded into the well marked “ladder” 
and 1 uL of RNA into each of the 12 wells. The Chip was placed on the adapted vortexer 
and mixed for 1 min at 2400 rpm. Place the loaded Chip in the Bioanalyzer and run the RNA 
program	as	recommended	by	the	manufacturer.
4.1.20	 Estimation	of	library	size
	 The	 size	of	 a	 library	 is	 correlated	 to	 the	number	of	 individual	 colonies	harvested	 to	
generate the library DNA pool. Four methods were used to estimate the size of the generated 
library.	
a.  Estimation by titration.
	 10	µL	from	a	1	mL	transformation	culture	was	diluted	with	90	µL	of	SOC	media	for	a	





  Number of colonies  x dilution factor x 100 (1 mL volume) x 
	 	 2	(2	mL	culture	per	plate)	x	41	(number	of	plates)	
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  Number of colonies x dilution factor x 10 (1 mL final volume)  
	 	 x	2	(2	mL	per	plate)	x	41	(number	of	plates)
	 	








  Number of colonies  x dilution factor x 2.5 (2 mL per plate)
	 	 x	41	(number	of	plates)
d.  Estimation by plating lower volume on 25 x 25 cm agar plates
	
	 50	µL	(20	x	dilution)	and	100	µL	(10	x	dilution)	from	the	1	mL	transformation	culture	
was plated on the 25 x 25 cm 2YT (100 µg/mL Amp + 2 % Glu) agar plates. Plates were left 
to	dry	and	 incubated	o/n	at	37°C.	The	number	of	colonies	on	each	spot	was	calculated	and	
extrapolated	to	estimate	the	number	of	colonies	available.	Formula	used	was:-





 Plasmid DNA (pRSET-BH6) from E. coli was purified using the Qiagen MiniPrep 
DNA kit according to the manufacturer’s instructions. The desired purified plasmid DNA was 
electroporated	 as	 described	 earlier	 using	 electrocompetent	E. coli	 cells	 BL21	 Star™(DE3)	




OD600 of 0.7. Protein expression in cells were induced with 1 mM (final conc.) of IPTG. Culture 
was	left	to	incubate	for	3	to	4	hr	with	contant	shaking	(180	rpm).	Cells	were	pelleted	in	50	mL	
fractions by centrifugation (4000 rpm, 30 min). Pellets were frozen at -20°C until use.
4.2.2	 Preparation	of	proteins	under	native	conditions
	 Frozen	pellets	of	proteins	were	resuspend	in	3	mL	of	native	lysis	buffer	I	with	3	µL	of	
lysozyme (stock 20 mg/mL). Pellets were resuspend gently with slow pipetting movements and 
incubated	for	30	min	on	ice.	The	lysate	was	sonicated	3	times	for	20	sec	with	20	sec	intervals	
on	ice.	The	lysate	was	transfered	to	2	x	2	mL	Eppendorf	tubes.	The	tubes	was	centrifuged	for	
10	min	at	12000	 rpm.	50	µL	of	 the	 supernatant	was	 removed	 for	SDS	gel	 analysis	 and	 the	
remaining supernatant for purification. The remaining pellet was used for preparation under 
denatured	conditions.
4.2.3	 Preparation	of	proteins	under	denatured	conditions
 Pelleted cells was resuspend in 500 µL of 8 M Urea. The pellet was resuspended well 
and	subjected	to	sonication	for	15	min	in	a	water	bath.	The	lysate	was	centrifuged	for	10	min	at	
12000	rpm	to	pellet	cell	debris.	50	µL	of	the	supernatant	was	used	for	SDS	gel	analysis	and	the	
remaining supernatant for purification. The pellet was discarded.
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4.2.4	 Preparation	of	periplasmic	proteins
	 Cell	 pellet	was	 resuspended	 in	 1	mL	of	 ice	 cold	 1x	TES.	Careful	 resuspension	was	
carried	out	 to	 avoid	 cell	 rupture.	 1.5	mL	of	 1	 to	 5	 dilution	of	 ice	 cold	 1x	TES	was	 added.	
Preparation was incubated on ice for 30 min. The supernatant was collected by centrifuging at 
4000	rpm	for	30	min.	The	supernatant	was	kept	at	4°C	until	use.
4.2.5	 His	Tag	purification	using	Ni-NTA	columns	under	native	conditions
 1 mL bed volume of 50% Ni-NTA agarose (Qiagen) was packed in a 12 mL empty SPE 
column (Phenomenax). The column was equilibrated with 20 mL of native lysis buffer I. The 
supernatant	from	the	native	preparation	or	periplasmic	preparation	was	added	to	the	column.	
The supernatant was allowed to drain by gravitational flow until the last drop. Care was taken 
to	ensure	the	column	would	not	dry	up.	The	column	was	subjected	to	2	wash	steps	with	10	mL	
wash buffer per wash. Proteins were eluted in 4 x 2 ml fractions using the elution buffer.
4.2.6	 His	Tag	purification	using	Ni-TED	columns	under	native	conditions
	
 The Protino Ni-TED columns (1 mL bed volume) were equilibrated with 4 mL of 
supplied	1x	LEW	buffer.	The	supernatant	from	the	native	preparation	or	periplasmic	preparation	





 The kit was equilibrated to room temperature. The Monoavidin column (Pierce) was 
equilibrated with 8 mL of PBS. 6 mL of Biotin Blocking and Elution Buffer was passed through 
the column to block any non-reversible biotin binding sites. 12 mL of Regeneration Buffer was 
added	to	remove	biotin	from	the	reversible	binding	sites.	The	column	was	washed	with	8	ml	of	
PBS. Add the supernantant to the column and allow it to pass by gravitational flow. After the 
entire sample had passed through the column, 0.25 mL of PBS was added to force sample 
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 Periplasmic supernatant was either filtered using a syringe filter with low protein binding 
or centrifuge at 3500 rpm for 15 min to remove debris. The 1 mL Fast Flow Protein L column 
(Pierce) was equilibrated using 5 mL of PBS. Supernatant was passed through the protein L 





 Determination of protein concentration was carried out using the Pierce 660 nm Protein 
Assay	kit	with	a	working	range	between	50-2000	µg/mL	for	microplate	procedure.	10	µL	of	each	
standard	(7	samples,	ranging	from	125	to	2000	µg/mL,	stored	at	4°C)	was	added	in	replicates.	
10 µL of sample and a blank sample (PBS) was added to a microplate well (Falcon ®, 96-well 
PVC (flexible) flat-bottom plate). 150 µL of the Protein Assay Reagent was added to each well 
and mixed by shaking. Plate was incubated at room temperature for 5 min. The absorbence was 
read at 660 nm wavelength using the SpectraMAX 250 MTP spectrophotometer.
4.2.10	 SDS	PAGE	analysis




of 200 mA and 400 V in a X Cell4 SurelockTm Midi cell or X Cell Sure LockTM Mini-Cell 
depending on the gel size for about 35 min in 1x MES buffer. 5 µL of the pre-stained Precision 




solution for staining. For analytical purposes, Coomassie brilliant Blue GLR 250 was used. 
The	gel			was	incubated	for	40	min	at	rt	with	show	shaking.	The	stained	gel	was	destained	with	
a	destaining	solution	for	40	min	at	rt	with	slow	shaking.	The	gel	was	transfered	to	ddH2O	and	
slowly shaked overnight at RT. The gel was submerged in 5 % aqueous glycerol  for long term 
storage.	
 Alternatively, the PAGE Blue staining kit (Fermentas) was used to stain the gels. The 
gel	was	washed	twice	with		ddH2O	by	slowly	shaking	for	10	min	per	wash.	The	gel	was	then	




 For Silver staining, the SERVA Silver Staining Kit (SERVA Electrophoresis) was used. 




(10	mL	sivler	nitrate	 in	100	mL	ddH2O)	 for	15	min	with	gentle	 agitation.	Two	quick	wash	
steps	of	10	sec	each	was	done	with	30%	ethanol.	Developement	of	the	gel	was	done	with	the	
developing	solution	(20	mL	Sodium	carbonate	solution	with	100	mL	ddH2O	and	50µL	of	37%	






 Prior to performing Western immunoblots, proteins of interest were run on a NuPAGE 
4-12 % Bis-Tris gel as described. Meanwhile, four sheets of Whatman® paper and one sheet 
of PVDF-membrane (Millipore) or Hybond ECL Nitrocellulose membrane (GE Healthcare) 
were	 cut	 according	 to	 the	 dimensions	 of	 the	 separation	 gel	 (5.5	 cm	 x	 9	 cm).	All	 sheets	 of	
Whatman® paper were soaked in transfer buffer at a time and placed onto the anode of the 
Western apparatus. The PVDF membrane was submerged for ~10 sec in 100 % ethanol and 
soaked for ~30 sec in transfer buffer before it was placed on top of the Whatman® paper on 
the apparatus. For the Hybond ECL Nitrocellulose membrane, it was soaked for ~30 sec in 
transfer buffer before being placed on top of the Whatman® paper. The separation gel was laid 
air-bubble free onto the membrane and, on top, the remaining Whatman® papers were placed. 
The	cathode	of	the	apparatus	was	connected	and	running	the	apparatus	for	80	min	at	40	mA	to	
performed the electrophoretic transfer of the proteins from the gel to the PVDF membrane.
4.2.14	 Immunostaining
 The immunostaining technique offers a possibility for specific staining of membrane 
transferred	proteins	with	conjugated	antibodies	or	binding	proteins.	Fristly,	 the	western	blot	
was	 incubated	 in	 blocking	buffer	 for	 1	 hr	 at	 rt.	All	wash	 steps	 in	 between	 incubation	were	
done twice for 5 min in PBS-T. The blocked membrane was incubated for 1 hr at rt with the 
conjugated binding partner. Development was carried out using CN/DAB staining (Thermo 
Scientific). Conjugated secondary antibodies were used when conjugated primary antibodies 
were	not	available.	
4.2.14	 Mass	spectrometry	identification	of	proteins
The protein bands analyzed by SDS-PAGE were subjected to in-situ trypsinolysis and 
microcrystalline layers of α-cyano-4-hydroxycinnamic acid (CHCA) were prepared on 
AnchorChips	384/600	as	described	[166].	Mass	spectrometric	analysis	was	performed	on	a	Scout	
MTP Ultraflex II MALDI-TOF-MS/MS equipped with a SmartBeam laser (Bruker Daltonics, 
Bremen, Germany), equipped with a solid-state SmartBeam laser. Positively charged ions in the 





was performed using the algorithm SNAP with a signal-to-noise threshold of 6. Internal mass 
correction	was	performed	using	 the	 signals	 of	 two	 reference	peptides	 (Angiotensin	 I,	MH+	
1,296.6853	(monoisotopic	mass),	and	ACTH	(18-39),	MH+	2,465.1989)	included	in	the	MALDI	
matrix	solution.	
 Protein identification was performed using the Mascot software 2.2 (Matrixscience, 
London, UK) searching the UniProt/Swiss-Prot and UniProt/Trembl sequence databases. The 
following	settings	were	used	for	the	searches:	mass	error	tolerance	for	peptide	masses:	15	ppm;	
mass error tolerance for the fragment ions: 0.35 Da; fixed modification: carbamidomethylation; 
variable modification: methionine oxidation; number of missed cleavage sites: 1; type of 
instrument: MALDI-TOF-PSD. Identifications based on PMF were considered very likely to 
be correct if the score was greater than 80. For identification by MS/MS a different score is 
calculated and in this case above threshold for identification was set to 50.
	 All	mass	spectrometry	analysis	was	carried	out	by	the	conducted	by	the	Mass	Spectrometry	
team at the Max Planck Institute for Molecular Genetics (courtesy of Dr. Nordhoff). 
4.3	 Phage	display	based	methods
4.3.1	 Helper	phage	preparation
 A 1:10 dilution series of M13K07 Helper phage stock was prepared in PBS by adding 
10 µL phage to 90 µL PBS. Top Agar was heated up and left to cool down to 43°C in a water 
bath. Polypropylene tubes were filled with 4 mL of Top agar. 200 µL of E. coli	culture	and	100	
µL of the phage dilution (10E-7 – 10E-11) were mixed and pour onto a 2YT Agar plate. Plates 
were	 left	o/n	at	37	°C.	A	single	plaque	was	picked	and	inoculated	 in	4	mL	2YT	(60	µg/mL	
Kan).	The	culture	was	incubated	at	37°C	with	constant	shaking	until	turbid	(3-4	hr).	1	mL	of	the	














 7.5 mL of ice cold 20% PEG / 2.5 M NaCl was added to 42.5 mL supernatant and left on 
ice for 1 hr. Tubes were centrifuged at 4000 rpm for 30 min. The supernatant discarded. Now, 
a white phage pellet should be visible. Pellet was left to dry for ~5-15 min up side down in a 





 5 mL of 2YT was innoculated in a 15 mL PP tube with a single clone of TG1 from an 
agar	plate	and	grown	shaking	overnight	at	37°C	and	250	rpm.	0.5	mL	of	overnight	TG1	culture	
was innoculated in 50 mL 2YT using a 250 mL Erlenmeyer flask and incubate shaking at 37°C 
and	250	rpm	until	OD600 = 0.4 – 0.5. A 1:10 serial dilution (until 10
-9)	was	prepared	from	the	
enriched phage libraries from selection rounds by adding 10 µL phage to 90 µL PBS-T in a 96-

















with 1.5 mL PBS-T and 1x 5 min with 1.5 mL PBS at rt. At the mean time, (a) 100 – 200 µg 
biotinylated protein antigen, or alternatively (b) 1 – 2  µg biotinylated peptide antigen were 
dissolved in 1 mL PBS. The wash solution was discarded, the magnetic beads resuspended 
gently	in	the	1	mL	antigen	solution	and	incubated	for	1	hr	at	rt	on	a	rotator.	Alternatively,	the	
incubation	can	be	performed	o/n	at	4°C	on	a	rotator.	The	antigen	solution	was	removed	and	
the magnetic beads washed 3x 5 min with 1.5 mL PBS-T. Finally, the last wash solution was 







 250 mL Erlenmeyer flask and incubate shaking at 37°C and 250 rpm until the culture  
	 reaches	an	OD600 = 0.4 – 0.5.
3. Bead-plate was arranged. Positions A1 – A12 of a 96-well V-bottom PP (PP) microtiter 
 plate were filled with 180 µL PTM and for each antigen 20 µL from corresponding  
 antigen-loaded bead stocks were added to the specified position. Magnetic beads of  
	 antigen	1	were	added	to	positions	A1,	beads	of	antigen	2	to	positions	A2,	and	so	on.	
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 For the first round selection continue with step 4. For later selection rounds, continue  
	 with	step	7.
4. Unselected antibody phage library were pre-incubated with empty magnetic beads in  
 PTM to deplete binders to the selection matrix. In a 15 mL PP tube, 2 mg (200 µL)  
	 Dynabeads	M-280	Streptavidin	was	added	to	1	x	1013 – 3 x 1013	phage	particles	in	10		
 mL PTM. The mixture was incubated for 1 – 2 hr at rt on a rotator.
5.	 Beads	were	concentrated	at	the	bottom	of	the	tube	by	centrifugation	for	2	min,	2000		
	 rpm	and	the	antibody	phage	library	solution	was	carefully	transfered	to	a	new	15	mL		
 PP tube. The magnetic beads were discarded.
6. The phage-plate for the first round was arranged. Positions A1 – A12 of a 96-well    
 V-bottom PP microtiter plate were filled with 200 µL of the antibody phage library  
	 solution.	
	 Continue	with	step	8.	
7. For the remaining rounds, the phage-plate were prepared. Positions A1 – A12 of a  
 96-well V-bottom PP microtiter plate were filled with 100 µL PTM. 100 µL of the  
 amplified amplified phage solutions of the previous round were added according to the  
 same antigen order in positions A1 – A12.
8. Wash plate(s) were prepared. Positions A1 – A12 of a 96-well V-bottom PP microtiter  
 plates were filled with 200 µL PBS-T. The number of plates were adjusted according  
	 to	Table	4.3.
9. The release plate was prepared by filling positions A1 – A12 of a 96-well V-bottom PP  
 microtiter plates with 200 µL PBS.




 up-and-down in the wells at medium speed (30 – 50 mm/sec). The program ends by  
	 releasing	the	beads	in	the	release	plate.	
 11. Once the Panning program finishes, E. coli culture plates were prepared. Positions A1  
 – A12 of a 96-well U-bottom PP microtiter plates were filled with 200 µL of E. coli   
 TG1	(OD600 = 0.4 – 0.5), E. coli	culture	plate	was	placed	in	the	instrument	and	started		
 the Transfer Program. This program simply transfers the beads from the release plate  





Plate Panning	Round	1 Panning	Round	2 Panning	Round	3 Panning	Round	4
1 Bead	plate Bead	plate Bead	plate Bead	plate
2 Phage plate Phage plate Phage plate Phage plate
3 Wash	plate Wash	plate	1 Wash	plate	1 Wash	plate	1
1 Release plate Wash	plate	2 Wash	plate	2 Wash	plate	2
2 E. coli	culture	plate Release plate Wash	plate	3 Wash	plate	3
3 - E. coli	culture	plate Release plate Wash	plate	4
1 - - E. coli	culture	plate Release plate
2 - - - E. coli	culture	plate
Time ~ 135 min ~ 145 min ~ 155 min ~ 165 min
Table	4.4:	Automated	Magnetic	Bead-Based	Panning	Protocol	(Round	4).
Plate Plate name Work	step Volume (µL) Time	(min)
1 Bead	plate Blocking	of	antigen-loaded	and	con-
trol magnetic beads with PTM
200 60
2 Phage plate Incubation	of	magnetic	 beads	 in	 an-
tibody	 phage	 stocks	 of	 the	 selection	
rounds
200 60
3 Wash	plate	1 Wash 1 of magnetic beads in PBS-T 200 10
4 Wash	plate	2 Wash 2 of magnetic beads in PBS-T 200 10
5 Wash	plate	3 Wash 3 of magnetic beads in PBS-T 200 10
6 Wash	plate	4 Wash 4 of magnetic beads in PBS-T 200 10















 medium (37°C), mix thoroughly and 200 µL was transfered into a 96-well filtration  
 plate (MultiScreenHTS Plates with a hydrophilic Durapore PVDF membrane).   
 The selection stock plate was sealed again with breathable sealing film and the   
	 incubation	continued	in	a	microplate	shaker	overnight	at	37°C	and	1200	rpm.
2. To the filtration plate, 20 µL M13K07 helperphage (~ 109	phage	particles)	was	added,		
	 covered	with	a	plastic	lid	and	incubated	stationary	for	30	min	at	37°C.
3. The filtration plate was placed on top of a 96-well U-bottom PP microtiter plate and  
 fixed with sticky tape. A counter balance plate was prepared in similar fashion. 
4. The bacterial culture was filtered by centrifugation in microtiter plate holders (swing  
 out rotor) for 2 – 5 min at 2000 rpm.
5. The filtrate containing the remaining M13K07 helperphage was discarded.
6. Retained bacteria was resuspended in 220 µL pre-warmed 2YT-Amp + Kan + 2 %  
 Glu and transfered to a fresh 96-well U-bottom PP microtiter plate. Phage production  






 well filtration plate.
9. The filtration plate was placed on top of a new 96-well U-bottom PP microtiter plate  
 and fixed with sticky tape. 
10. Antibody presenting phage particles were filtered to remove possible E. coli	cells			
 remaining by centrifugation for 2 – 5 min at 2000 rpm.
11.	 Filtrate	(phage	stock	plate)	was	stored	at	4°C	until	used.
12. 50 µL PBS was added to each well of the phage stock plate and mix thoroughly. For  




	 The	 polyclonal	 antibody	 phage	 ELISA	 for	 evaluation	 of	 enrichment	 success	 was	
performed	 using	 a	magnetic	 particle	 processor	 to	maintain	 similar	 conditions	 as	 the	 initial	
selection	process.	At	a	maximum,	polyclonal	ELISA	for	 twelve	 independent	selections	over	
four rounds can be performed simultaneously with the appropriate negative control. Proposed 
plate	layout	for	12	ELISAs	in	parallel	and	an	example	of	a	polyclonal	ELISA	result	are	shown	
in	Figure	4.1.	The	ELISA	protocol	takes	4	hours	and	is	summarised	in	Table	4.5.	
1. Bead-plate arranged by filling each position of a 96-well V-bottom PP microtiter plate  
 with 180 µL PTM and 20 µL of antigen-loaded bead stock according to plate layout  
 in Figure 4.1. Magnetic beads of antigen 1 was added to positions A1 – D1, beads of a 
 antigen 2 to positions A2 – D2, and so on. 
2.	 As	a	negative	control,	empty	beads	were	used.	5	mg	(500	µL)	Dynabeads	M-280		 	
 Streptavidin magnetic beads were washed 3x 5 min with 1.5 mL PBS-T and 1x 5 min  
 with 1.5 mL PBS at rt. The last wash solution was discared and beads resuspend in 1  
 mL PBS. 20 µL was added to positions E1 – H12.
3. Phage-plate was arranged by filling each position of a 96-well V-bottom PP microtiter  
 plate with 150 µL PTM. 50 µL of phage solution from the phage stock plates of the  
 individual rounds were added to the plate according layout in Figure 4.1. Phage stocks  
 of selection rounds 1 – 4 was added on antigen 1 to position A1 – D1 and E1 – H1,  
 respectively. Phage stocks of selection rounds 1 – 4 were added on antigen 2 to   
	 position	A2-D2	and	E2-H2,	respectively,	and	so	on.
4. Wash plates 1 – 3 were prepared. 96-well V-bottom PP microtiter plates were filled  
 with 200 µL PBS-T.
5. Wash plate 4 was prepared by filling the 96-well V-bottom PP microtiter plates with  
 200 µL PBS.
6. For the antibody plate, 4 µL of mouse monoclonal anti-M13-HRP was added to 20  
 mL PTM (1:5000). The 96-well V-bottom PP microtiter plates were filled with 200 µL  
	 antibody	solution.



















Plate Plate name Work	step Volume (µL) Time	(min)
1 Bead	plate Blocking	of	antigen-loaded	and	con-
trol magnetic beads with PTM
200 60
2 Phage plate Incubation	of	magnetic	 beads	 in	 an-
tibody	 phage	 stocks	 of	 the	 selection	
rounds
200 60
3 Wash	plate	1 Wash 1 of magnetic beads in PBS-T 200 10
4 Wash	plate	2 Wash 2 of magnetic beads in PBS-T 200 10
5 Antibody	plate Incubation	 of	 antigen-loaded	 and	
control	beads	with	mouse	anti-M13-	
HRP-conjugated, 1:5000 in PTM
200 60
6 Wash	plate	3 Wash 3 of magnetic beads in PBS-T 200 10
7 Wash	plate	4 Wash 4 of magnetic beads in PBS-T 200 10
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On	 the	 left,	 the	plate	 layout	 for	12	 individual	 selections	 is	 shown.	For	 each	 selection	 the	phage	
stock solutions are split and pipetted into the positions A – D and E – H of the same column, 
respectively. Next, selection target-coated or control protein-coated magnetic beads are added to the 
phage	solutions	as	indicated.	All	steps	of	the	ELISA	are	performed	in	a	96-well	magnetic	particle	
processor. On the right, the enrichment of specifically binding antibody phage during 4 rounds of 
selection on GRB2 is shown. Specific enrichment is seen in rounds 3 and 4.
4.3.6	 Evaluation	of	phage	selections
4.3.6.1	Picking	monoclonal	antibody	fragment	presenting	cells




Glu). Plates were incubated o/n at 37°C. 92 single phagemid colonies were picked into a MTP 
containing	200	µL	of	2YT	(Amp	+	2	%	Glu)	in	HMFM	media	and	grown	o/n	at	37°C,	1400	






(Amp + 2 % Glu) in a 96-well U-bottom PP microtiter plate. Culture was grown o/n at 37°C, 
1400	rpm.	10	µL	of	the	o/n	culture	was	innoculated	to	200	µL	of	pre-warmed	(37°C)	2YT	(Amp	





 Phagemid DNA (pTSL phagemid series) from E. coli was purified using the Qiagen 
MiniPrep DNA kit according to the manufacturer’s instructions. The desired purified plasmid 




µg/mL	Amp	+	0.1	%	Glu	)	until	an	OD600 of 0.4-0.5. Protein expression in cells were induced 
with 1 mM (final conc.) of IPTG. Culture was left to incubate for 3 to 4 hr with contant shaking 






 sealing film and incubated for 2.5 hr at 37°C and 1200 rpm. 200 µL of pre-warmed  
	 2YT-Amp	+	2	%	Glu		medium	(37°C)	was	added	to	the	plate,	mixed	thoroughly	and		
 200 µL was transfered into a 96-well filtration plate (MultiScreenHTS Plates with  
 a hydrophilic Durapore PVDF membrane). The selection stock plate was sealed again  
 with breathable sealing film and the incubation continued in a microplate shaker   
	 overnight	at	37°C	and	1200	rpm.
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3. 20 µL M13K07 helperphage (~ 109 phage particles) was added to the filtration plate,  
	 covered	with	a	plastic	lid	and	incubated	stationary	for	30	min	at	37°C.
4. The filtration plate was placed on top of a 96-well U-bottom PP microtiter plate and  
 fixed with sticky tape. A counter balance plate was prepared in similar fashion. 
5. The bacterial culture was filtered by centrifugation in microtiter plate holders (swing  
 out rotor) for 2 – 5 min at 2000 rpm.
6. The filtrate containing the remaining M13K07 helperphage was discarded.
7. Retained bacteria was resuspended in 220 µL pre-warmed 2YT-Amp + 2 % Glu and  
 transfered to a fresh 96-well U-bottom PP microtiter plate. Phage production   




 to a 96-well filtration plate.
9. The filtration plate was placed on top of a new 96-well U-bottom PP microtiter plate  
 and fixed with sticky tape.
10. Antibody presenting phage particles were filtered to remove possible E. coli	cells			
 remaining by centrifugation for 2 – 5 min at 2000 rpm.
11.	 Filtrate	(antibody	presenting	phage)	was	stored	at	4°C	until	used.
4.3.6.5	Monoclonal	ELISA	with	soluble	antibody	fragments
 Half of the NUNC 96 well MaxiSorb ELISA plate was coated with 100 µL of antigen 
(10 µg/mL in PBS) and the remaining half with PTM for 1 hr at rt. The solutions were discarded 
by tapping the plates on a linen towel. The plates were washed 3 x with PBS-T by gentle 
agitation. All the surfaces of the wells were blocked using 500 µL PTM and incubated for 1 hr at 
rt. The blocking solution was discarded and plates washed 3 x with PBS-T. 100 µL of PTM was 
added to the first half of the plate coated with antigen. 100 µL of soluble antibody supernatant 
was added to the PTM, mixed and 100 µL transferred to the PTM coated half (eg. A1 to A7, A3 
to	A9	and	so	forth).	The	plate	was	incubated	for	1	hr	at	rt.	The	solutions	were	discarded	again	
and the wash step repeated. 200 µL of Protein L-HRP (1:5000 in PTM) was added to each well 
and	incubated	for	1	hr	at	rt.	The	solution	was	discarded	and	the	wash	step	repeated	again.	100	
µL	of	the	developing	substrate	was	added	to	each	well	and	left	to	develop	for	30	min	and	rt	in	




 Half of the NUNC 96 well MaxiSorb ELISA plate was coated with 100 µL of antigen 
(10 µg/mL in PBS) and the remaining half with PTM for 1 hr at rt. The solutions were discarded 
by tapping the plates on a linen towel. The plates were washed 3 x with PBS-T by gentle 
agitation. All the surfaces of the wells were blocked using 500 µL PTM and incubated for 1hr 
at rt. The blocking solution was discarded and plates washed 3 x with PBS-T. 100 µL of PTM 
was added to the first half of the plate coated with antigen. 100 µL of antibody presenting phage 
solution was added to the PTM, mixed and 100 µL transferred to the PTM coated half (eg. A1 to 
A7,	A3	to	A9	and	so	forth).	The	plate	was	incubated	for	1	hr	at	rt.	The	solutions	were	discarded	








affinity determination of antibodies in solution [167]. As protein L will capture kappa light 
chains,	the	phages	recovered	by	the	protein	L	beads	would	have	both	the	antibody	heavy	and	
light	chain	assembled	properly	and	presented	on	the	phage	surface.
 Protein L-Biotin was coupled to the magnetic beads using the antigen loading protocol 
described earlier. Using a phage library of known cfu, a 1:10 dilution series of the phage library 
in	the	titre	range	of	108	to	101 cfu was prepared in 100 µL PBS. Add 100 µL of the dilution 
series to the second row of the 96-well U-bottom PP microtiter plate filled with 100 µL of PTM. 
10 µL of Protein L coupled beads werea added to 200 µL of PTM in the first row of the MTP. 
Using the MPP, beads were trasnferred from Row 1 to Row 2 containing phage. The beads 
were incubated in the phage solution for 1 hr using the MPP with constant magnet movements 
as described in the panning procedure. Beads were washed using the MPP with 200 µL PBS-T. 
The beads were released in 100 µL of PBS after the wash. 100 µL of the phage dilutions in PBS 
wereinfected	with	100	µL	of	TG1	culture	with	an	OD600	=	0.4-0.5.	The	culture	was	incubate	at	
RT for 30 min without shaking. 100 µL of infected TG1 cells were plated on 10 cm 2YT Agar 





a.  Phage Display Panning.
	
 Phage display panning was carried out using the semi-synthetic scFv library based on 
a single human framework for VH (V3-23/DP-47 and JH4b) and Vκ (O12/O2/DPK9 and Jκ1) 





 DNA was prepared from overnight E. coli	cultures	of	a	single	scFv	clone	(4IE3)	and	
from selection rounds 2, 3 and 4 using a MiniPrep Kit (Qiagen, Hilden, Germany). The final 
volume for all PCR reactions was 20 µL containing 0.4 µL of cDNA, 200 µM dNTPs, 0.2 µM 
of forward primer, 0.2 µM reverse primer (Invitrogen, Karlsruhe, Germany) and 1 x Phusion 
HF reaction buffer (New England Biolabs, Frankfurt, Germany). The amount of polymerase 
used was 0.2 µL of 2 U/µL of Phusion Taq from New England Biolabs, per reaction. All 
reactions were carried out using a MJ Research PCT-200 PCR machine. After heating at 95°C 
for	45	sec,	we	performed	30	cycles	(30	sec	at	95°C,	30	sec	at	55°C	and	30	sec	at	72°C)	and	
ended after 5 min at 72°C. PCR amplification was of the variable heavy chain region was 
carried out using VH-NcoI-Fw (ACATGCCATGGCCGAGGTGCAGC) and VH-XhoI-Rv 
(CCGCTCGAGACGGTGACCAGG) primers. PCR amplification of the variable light chain 
was carried out using VL-SalI-Fw (AGCGGGTCGACGGACATCCAGATG) and VL-NotI-Rv 
(AAGGAAAAAAGCGGCCGCCCGTTTGATTTC) primers. All PCR products were purified 
using the PCR Purification Kit (Qiagen) and eluted in 30 µL of distilled water. The band size 
was approximately between 350 to 370 bp. DNA concentration was determined using NanoDrop 
ND-1000 (Thermo Fischer Scientific, Dreieich, Germany)
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c. Optimisation of the DiVE Assay to the study of PCR amplicons.
 For optimisation, 350 ng of VH amplicon from 4IE3, round two and round four of 
positive	enrichment	selection	rounds	was	used.	Amplicons	were	subjected	to	heat	denaturation	
at	98°C	for	10	min	and	re-annealing	at	60°C	for	5	min	before	nuclease	treatment.	For	temperature	
optimization, 1 U S1 nuclease (Roboklon GmbH, Berlin, Germany) was used with 30 min 
incubation at 65°C. S1 nuclease titration was carried out using 0.02 U, 0.1 U and 0.2 U of S1 
nuclease	with	30	min	incubation	time.	The	reaction	was	stopped	by	adding	2	µL	of	0.5	M	EDTA	
(pH	8).	Optimisation	 of	 incubation	 times	was	 carried	 out	 at	 65°C	with	 three	 different	 time	
points (10, 20, and 30 min) using 0.2 U of S1 nuclease.
d. Application of DiVE Assay to monitor phage display panning rounds.
 Both positive enrichment selection rounds were PCR amplified using the V-gene primers 
for heavy and light chain as described above. A total amount of 350 ng of DNA was used in a 50 
µL reaction volume. Each reaction mix prepared contains the 0.5 X S1 reaction buffer (20 mM 
NaCH3COO-, 0.15 M NaCl, 1 mM ZnSO4) and distilled water to a final volume of 46 µL. The 
reaction	mix	was	subjected	to	the	denaturing	and	re-annealing	process	using	the	thermocycler	
as described above. 0.04 U of S1 nuclease was added to each reaction and incubated further at 
65°C	for	10	and	20	min.	2	µL	of	0.5	M	EDTA	was	added	to	each	sample	to	stop	the	enzyme	
activity.	
e. Analysis of DiVE assayed amplicons using electrophoresis.
	
	 A	1%	agarose	gel	with	ethidium	bromide	was	prepared.	A	1:10	dilution	of	the	100	bp	
plus DNA ladder (Fermentas, St. Leon-Rot , Germany) was prepared using 1 X S1 reaction 
buffer (Roboklon GmbH, Berlin, Germany). Equal amounts of DNA were loaded on the gel for 
separation.
f. Batch sequencing of amplicons from all rounds.
 PCR amplicons of the heavy and light variable regions was subjected to batch sequencing 










































with	NcoI	 and	BamHI	 and	 ligated	 to	 the	 digested	 pHAL	 vector	 resulting	 in	 pTSL	Parking	
Vector.	
	 pSABA	vector	was	digested	with	XmaI	and	HindIII	to	obtain	the	LC	fragment	(PhoA	












fragment	 from	pTSL	Parking	2	and	opened	 the	pTSL	Parking	3	at	 the	HindIII	cut	site.	The	
PhoA-LC	fragment	was	ligated	into	the	pTSL	Parking	3	vector	at	the	HindIII	site.	Orientation	



























Vector Ab	format Format	Switch Light	Chain Heavy	Chain
pTSL1 IgD	Fab scFv	to	IgD	Fab SalI NotI NcoI XhoI
pTSL2 IgG	Fab scFv	to	IgG	Fab SalI NotI NcoI XhoI
pTSL3 Full	Fab Any	isotype	Fab SalI NheI NcoI MluI




































DB3.1	 							DH10B DB3.1	 							DH10B







	 Variable	 regions	 for	 heavy	 and	 light	 chains	 were	 amplified	 via	 PCR	 from	 a	 Maxi	
preparation	of	the	Tomlinson	semi	synthetic	antibody	library.	The	variable	heavy	chain	region	
was	amplified	using	the	primer	pair	of	VH-Tom-NcoI-Fw	and	VH-Tom-XhoI-Rv.	The	amplicon	






















amplified	 (Figure	 5.6).	The	 fragment	was	 gel	 purified	 using	 the	Qiagen	Gel	Extraction	Kit	
and	digested	using	NotI	to	remove	the	LC	ccdB	cassette.	The	remaining	1.6	Kb	fragment	was	
gel	purified	(Figure	5.7).	The	variable	light	chain	fragments	were	also	digested	with	NotI	and	







































































































a.  Vector preparation for sub-cloning.
	 The	vector	pTSL2	and	the	VH-VL-cloning	cassette	for	IgD	and	IgG	Fab	were	digested	
with	SalI	and	MluI.	The	VH-VL-cloning	cassettes	were	purified	using	the	PCR	purification	kit	




order	 to	 ensure	 low	 religation	 from	 the	dephosphorylated	vector,	 a	 test	 transformation	with	





SalI/MluI	 digested	 pTSL2	 not	 ligated,	 (B.)	 Religation	 of	 SalI/MluI	 digested	 pTSL2,	 (C.)	Uncut	 pTSL2,	 (D.)	
pUC18	Control.	DB3.1	cells	were	used	on	the	left	panel	and	DH10B	cells	were	used	on	the	right	panel.
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c.  Determination of library diversity.
	 The	diversity	of	the	libraries	were	estimated	using	four	different	protocols	as	described	











1 2 3 4a 1 2 3 4a
100 -b 9.0x106 8.3x107 3.6x107 - 2.4x107 3.5x107 2.2x107
1000 - 6.6x106 8.6x107 3.2x107 - 1.5x107 2.9x107 2.0x107
10000 - 1.6x107 4.5x107 - - -c 2.2x107 -






d.  Colony PCR evaluation of library clones.
	 Colony	PCR	was	carried	out	using	LMB	and	pIII	primer	pair	to	amplify	the	entire	VH-





e.  Sequencing of clones from library preparation.
	 48	 clones	were	 selected	 and	 sequenced	using	 the	 sequencing	primers	 for	 heavy	 and	














































Chain Light	Chain Heavy	Chain Light	Chain Heavy	Chain
No.	of	clones	with	
insert
46 45 47 46
%	of	clones	with	insert	
per	chain












































































































































processes	 requires	 the	 antigens	 to	 be	 biotinylated,	 the	 success	 of	 the	 biotinylation	was	 also	





and	Ubi8	were	 cloned	 in	 the	E. Coli	 expression	 vector	 pRSET-BH6	 and	 pRSET-BH6-GW,	
respectively.	The	use	of	Ni-TED,	Ni-NTA	and	Monomeric	Avidin	for	antigen	preparation	was	
evaluated.	Each	has	specificity	to	different	attributes	on	the	proteins	(Figure	5.15)
Antigen Molecular	Weight	(kDa) Antigen Molecular	Weight	(kDa)
ATF4-A3 47 GST 30
ATF4-E2 47 MAPK9 55
ATF4-MPMG 47 ROA1 25
ATX2 56	/	28a SH3GL1 44
Cyclophillin 25 SH3GL2 43
eGFP 32 SH3GL3 40
GRB2 30 TPI-SV 30
GPS2 40 Ubi8 20
Note:	a	Protein	is	subjected	to	in	vivo	degradation.	
Table	5.6:	List	of	antigens	with	their	respective	molecular	wieight	evaluated	for	antibody	selection	





























Lane Fraction Lane Fraction
L Protein	Ladder E1 Elution	1
C Crude	Extract E2 Elution	2


























protein	 (Figure	 5.17).	 The	 high	 number	 of	 elution	 fractions	 required	 to	 remove	 the	 bound	
proteins	would	result	in	lower	concentrations	of	the	purified	protein.
Legend:
Lane Fraction Lane Fraction
L Protein	Ladder E1 Elution	1
C Crude	Extract E2 Elution	2
F Flow	Through E3 Elution	3
W1 Wash	1 E4 Elution	4
W2 Wash	2 E5 Elution	5









a.  Evaluation of expression levels of recombinant antigens.
	 All	16	antigens	considered	for	antibody	selection	process	was	evaluated	for	expression	
levels.	All	 antigens	were	 individually	 cloned,	 expressed	 and	 purified	 using	 the	His-tag	 via	
Ni-NTA	columns.	Figure	5.18	(A.)	shows	 the	coomassie	stained	SDS-PAGE	analysis	of	 the	
expression	 levels	 after	 purification.	 From	 the	 list	 of	 16	 initial	 antigens,	 only	ATF4-A3	 and	
ATF4-E2	were	not	expressed	.	GPS2	and	SH3GL1	showed	low	expression	levels.	The	remaining	
antigens	exhibited	good	expression	levels.	











b.  Evaluation of mass spectrometry and sequencing analysis of recombinant antigens.
	 For	MS	and	DNA	sequencing	analysis,	only	the	proteins	that	were	succesfully	expressed	
and	biotinylated	were	evaluated.	The	bands	of	the	expected	sizes	were	sent	for	mass	spectrometry	








Lane Antigen MW	(kDa) Lane Antigen MW	(kDa)
1 ATF4-A3 47 9 GST 30
2 ATF4-E2 47 10 MAPK9 55
3 ATF4-MPMG 47 11 UFM1 25
4 ATX2 56	/	28a 12 SH3GL1 44
5 Cyclophillin 25 13 SH3GL2 43
6 eGFP 32 14 SH3GL3 40
7 GRB2 30 15 TPI-SV 30






























Band Antigen MW	(kDa) Mascot	Score Band Antigen MW	(kDa)
Mascot	
Score
1 ATF4-MPMG 47 54 8 MAPK9 55 275
2 ATX2 56 na 9 UFM1 25 79
3 ATX2 28a 36 10 SH3GL1 44 64
4 eGFP 32 252 11 SH3GL2 43 101
5 GRB2 30 97 12 SH3GL3 40 201
6 GPS2 40 55 13 TPI-SV 30 113































































































































































































































































	 The	 antibody	 fragment	 presentation	 assay	 determines	 the	 amount	 of	 phage	 particles	
presenting	functional	Fab	fragments	from	both	IgD	and	IgG	Fab	libraries.	The	starting	material	







Figure	 5.20	 (B.).	 For	 IgD,	 an	 estimated	 4.9	 x	 106	 phage	 particles	 presented	 functional	 Fab	
fragments	on	 their	 surface.	The	amount	of	phages	presenting	 IgG	Fab	was	estimated	at	4.1	
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IgD Fab IgG Fab
y = -0.2991Ln(x) + 5.2417
R2 = 0.9178
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	 Many	experiments	 require	a	 rapid	and	cost	effective	method	 to	monitor	nucleic	acid	
sequence	diversity.	The	DiVE	(Diversity	Visualisation	by	Endonuclease)	assay,	allows	rapid	








on	the	gel.	Therefore	 the	differences	 in	band	intensities	allows	 	 the	user	 to	visually	monitor	
differences	in	diversity	.
5.5.1	 Optimisation	of	S1	nuclease	incubation	temperature	
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display	was	 used	with	M13KO7.	The	 other	was	 a	Combo	 strategy	 utilizing	 a	 combination	









the	Exclusive	Mono	method	 only	 had	 11	 antigens	 enriched	with	 no	 enrichments	 for	ATX2	







Lane Antigen MW	(kDa) Lane Antigen MW	(kDa)
M Protein	Ladder 7 MAPK9 55
1 ATF4-MPMG 47 8 UFM1 25
2 ATX2 56	/	28a 9 SH3GL1 44
3 eGFP 32 10 SH3GL2 43
4 GRB2 30 11 SH3GL3 40
5 GPS2 40 12 TPI-SV 30
6 GST 30 13 Ubi8 20
Note:	a	Protein	is	subjected	to	in	vivo	degradation.	



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Strategy Exclusive		Mono Strategy Combo
Round Helper	Phage Display Round Helper	Phage Display
1 M13KO7 Monovalent 1 Hyperphage Polyvalent
2 M13KO7 Monovalent 2 M13KO7 Monovalent
3 M13KO7 Monovalent 3 M13KO7 Monovalent
4 M13KO7 Monovalent 4 M13KO7 Monovalent




















	 Single	clones	were	 selected	 from	each	antigen	 for	 further	downstream	 investigation.	
Table	5.10	shows	the	sequences	of	the	CDR	regions	belonging	to	the	variable	regions	of	the	
heavy	and	light	chain	from	the	selected	clones.	The	monoclonal	ELISA	results	are	also	shown	
in	Table	5.10.	All	 clones	 exhibit	 the	highest	OD	 readings	 for	 their	 selections.	Although	 the	
allowed	 diversity	with	 the	DVT	 codon	was	 8	 amino	 acids,	 3	 unexpected	 codons	 encoding	
tryptophan,	valine	and	histidine	was	retrieved	from	2	scFv	clones	and	1	IgG	Fab	clone.	7	clones	
in	total	were	selected	for	format	switching	experiments.	
Antigen TPI-SV Antigen UBI8
Library Helper	Phage Round Library Helper	Phage Round
scFv M13KO7 3 scFv M13KO7 4
IgG Hyperphage 4 IgG Hyperphage 5


















































































	 To	 investigate	 the	 influence	 of	 	 different	 antibody	 formats	 on	 binding	 efficiency,	
individual	positive	clones	were	selected	to	sub	clone	the	corresponding	V-regions	into	different	








after	 format	 switching.	The	 intensity	of	 the	OD	 is	used	as	 a	 reference	of	binding	ability	of	







shows	 the	maintenance	of	binding	ability	of	 scFv	derived	daughter	clones	but	with	a	 lower	
efficiency	in	Fab	format.	Only	clone	2F	when	converted	from	scFv	to	IgG	Fab	showed	binding	















as	 the	 parental	 format	 and	 the	 subsequent	 conversions	 are	 termed	 daughter	 formats.	 scFv	 is	 connected	














scFv IgD IgG scFv IgD IgG scFv IgD IgG scFv IgD IgG scFv IgD IgG scFv IgD IgG scFv IgD IgG




















	 Table	5.11	shows	the	 individual	analysis	result	 for	each	primer	with	family	assigned	










































We	designed	3	new	primers	 to	allow	coverage	of	non-covered	V-genes	 that	 exhibit	binding	
interactions	(Table	5.15).






































using	 two	 reverse	 transcriptases	 (RTase).	 The	 commercially	 available	 SuperScript®	 II	 and	
totalscript-OLS®	were	applied	in	parallel	to	synthesise	total	cDNA	from	the	same	RNA	sample	



























combination,	 but	 with	 very	 low	 yield.	 Phusion	 gave	 the	 best	 amplification	 results	 of	 the	
three	tested.	The	VH	family	pool	(equimolar	concentrations	of	all	idiotype	forward	primers)	
resulted	in	very	poor	amplification,	indicating	that	primer	mixtures	decrease	amplification	yield	
significantly.	Attempts	 to	 improve	 the	conditions	by	varying	annealing	 temperatures	and	by	
addition	of	DMSO	did	not	enhance	amplification	(result	not	shown).	However,	optimisation	
of	 the	PCR	condition	 by	modifying	 the	MgCl
2


























































































































































similar	 distribution	 pattern	 of	 yield	was	 observed	 for	multiplexed	 as	well	 as	 single	 primer	
combinations.	
5.7.5	 Antibody	isotype	and	idiotype	amplification





























































































Total cDNA SuperScript II
Total cDNA TotalScript

















































































































would	 be	 required.	 This	 will	 result	 in	 an	 enourmous	 number	 of	 PCR	 amplifications	 thus	
increasing	the	time	and	cost	to	generate	a	naive	library.	
	 To	 circumvent	 this	 bottleneck,	 several	 parameters	 to	 decrease	 the	 number	 of	 PCR	
amplification	required	were	investigated.	Firstly	 the	use	of	a	combination	of	pooled	primers	
of	all	V-genes	were	used.	Although	able	 to	amplify	 the	 resulting	amplification	was	not	able	




investigated.	V-gene	 profile	 amplification	 from	 a	 pooled	 population	 of	 cDNA	and	 a	 pooled	
amplification	of	the	five	donors	was	conducted.	The	pooled	V-gene	profile	of	the	five	donors	
showed	a	profile	 that	 is	 close	 to	 that	of	 the	 individual	profiles	when	amplified	 individually.	
This	 	approach	would	then	be	able	to	overcome	the	complication	of	under	representation	of	
low	expressing	V-gene	families.	As	the	template	is	amplified	with	just	a	V-gene	primer,	less	






















































































	 The	 emergence	 of	 antibodies	 as	 immunotherapeutic	 and	 diagnostic	 tools	 has	 caused	
a rush to develop better recombinant human antibodies. Antibodies offer target specificity 
unrivalled by conventional therapies and diagnostic tools. The benefit of antibodies especially in 
terms of therapy has made it a multi billion dollar business with the approval of 18 monoclonal 
antibody therapies for various conditions [174]. The production of antibodies is still dependent 
largely on the traditional hybridoma technology, which requires the immunization of animals. 
However, over the last 20 years, various combinatorial technologies have been introduced 
which allows the development and selection of antibodies from an  in vitro immune repertoire 
without the need to immunize a living host [94,175,176,177]. Amongst the array of different 
display technologies, phage display is the most successful method to date for generating 
human therapeutic antibodies. Therefore, streamlining of the phage display process is still of 
general importance to help improve the existing protocols for human antibody generation. As 
a result, investigations into library design and generation parameters affecting human antibody 
generation by phage display was carried out. 
6.1		 Phagemid	vector	construction	
 In phage display, the most commonly used phage coat protein for antibody fusion is the 
minor coat protein III [178]. In phagemid vectors, only the phage packaging signal and pIII gene 
is provided. For phagemid systems, a helper phage such as M13KO7 is required for successful 
phage packaging. This is due to the lack of other genes encoding the packaging proteins in 
phagemid vectors for phage generation [179]. The pTSL phagemid vectors were designed with 
an	ampicilin	resistant	gene	and	a	lac	promoter	for	regulation	of	gene	expression.	The	phagemid	
vector has two origins of replication to allow the formation of pIII fused antibody fragment 
for phage packaging and bacterial expression. Each cloning site for both heavy and light chain 
regions are incorporated with a ccdB cassette. The toxicity of the ccdB gene has been used 
successfully for positive selection for cloning experiments with different antibiotic resistance 
[180,181]. Low transformation background was achieved with the use of the ccdB gene that 
permits toxicity to inhibit growth of re-ligated clones. This proved to be an advantageous feature 
to include in the phagemid vector for use in antibody library generation, as high transformation 
background would render the library generation process ineffective. The cloning sites in the 
pTSL vectors allow easy conversion in between different antibody formats.
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6.2	 Generation	of	semi-synthetic	antibody	library
 Common formats used for antibody libraries are scFv and Fab with the latter being 
more preferred due to the smaller size, lack of an interchain disulphide bond and presentation 
as a single peptide via a glycine-serine linker. The smaller scFv at 30 kDa would allow it to 
be expressed with much greater ease in bacteria than the larger Fab (50 kDa). The scFv being 
only a single polypeptide chain also allows easier fusion to the minor coat proteins of phages 
thus allowing better presentation efficiency than Fab constructs. This is because Fab constructs 
have to be expressed as two individual chains with either one of the heavy or light chain being 
fused to the phage coat protein. By transportation to the periplasmic region, the two chains 
combine via disulphide bond formation to form the Fab construct [182]. The IgG Fab format 
is more commonly used due to the ease of conversion from Fab to full IgG molecule with 
the preservation of affinity and binding [183,184]. The study of presentation efficiency and 
performance of different Fab formats is important due to some downstream limitations posed 
by the scFv construct. Limitations such as the lack of stability, tendency to multimerize and a 
short serum half life will limit the efficacy of scFv formats as a tool for therapy. Therefore, the 
comparison of two different Fab constructs from IgD and IgG isotype was carried out.
 The pTSL vector series were used to generate new semi-synthetic antibody libraries. 
The Tomlinson semi-synthetic scFv library was used to sub-clone two other libraries for this 
work to allow better comparison as the variable constructs originate from a single pool. A dual 
vector system where both heavy and light chain are cloned separately into two vectors and 
restriction enzyme ligation to sub-clone existing antibody libraries have been reported [185, 
186]. The dual vector system would require two sets of transformation to generate individual 
sub-libraries for both heavy and light chain. Here, the variable heavy and light repertoires were 
generated based on PCR assembly by amplifying the V regions of both chains, digesting with 
restriction enzymes, ligating and re-amplifying it to obtain the ligated fragments. This allowed the 
generation of the Fab constructs without the need of an intermediate transformation procedure or 
having to generate two sub-libraries which proves cumbersome. The transformation efficiency 
for both libraries using the pTSL phagemid vectors was comparable. Although generally the 
largest sized library is always anticipated because theoretically it would yield more binders 
for a larger repertoire of antigens [101], but this does not necessary result in a higher affinity 
antibody [187]. The use of TG1 strains for library generation was able to generate a library size 
of approximately 5 x 107 for both IgD Fab and IgG Fab libraries. DNA sequencing of a random 
test set of antibody clones showed the diversity of the clones was conserved.
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 To date, there has been only 3 known IgD derived antibody libraries made [109,188,189]. 
Raum	et al. managed to show the durability of the IgD Fab construct by converting the enriched 
IgD Fab fragments to full IgG1 constructs successfully. The ability of both IgD and IgG Fab 
constructs to be converted to full IgG molecules makes it an ideal format for comparison. The 
IgD Fab differs from the IgG Fab by virtue of the disulphide bond formation. Although the 
antibody fold is kept much in place, the different location of the interchain disulphide bond 
cysteine in both IgD and IgG allows a possible variation in forming functional Fab constructs to 
be presented on phage surfaces (Figure 6.1). Rather than performing a single clone comparison, 
the comparison of libraries was carried out to provide a better understanding on the overall 
performance of both constructs although single clone comparisons was also carried out later. 
Figure	6.1:	Teriary	and	secondary	structure	of	IgD	Fab	(PDB:	1ZVO)	and	IgG	Fab	(PDB:	1HZH).	
(A.) IgD Fab, (B.) IgG Fab. The red lines represent the beginning of the CH1 region for the IgD and the end 











 Before conducting antibody selection processes, antigens for selection must be prepared. 
The importance of high quality purified targets must not be overlooked as it can affect the 
selection process by enriching antibodies against contaminants. For the applied protocol, purified 
biotinylated antigens are required for coupling to magnetic beads. Antigens are recombinantly 
expressed using the pRSET-BH6 and pRSET-BH6-GW vectors where all proteins are expressed 
with a AVI-Tag and His-Tag. The AVI-Tag allows in vivo biotinylation to occur and the His-Tag 
functions as an affinity purification tag using IMAC.
 Several different purification strategies were evaluated to generate a purification strategy 
to obtain the highest possible quality antigens for phage display selection. Ni-TED and Ni-NTA 
were compared for affinity purification using the His-Tag. The yield and purity of antigens 
from Ni-TED was lower than Ni-NTA. Ni-TED is a pentadentate metal chelator thus occupying 
five out of the six possible binding sites in the coordination sphere of the Ni2+ ion. Ni-NTA 
occupies only four sites on the Ni ion thus having 2 active binding sites to capture proteins 
in comparison to only one free site with the Ni-TED. This extra binding site could contribute 
to the higher yield of the purification. Monomeric avidin was also investigated to study the 
possibility of using the biotinylation as a purification strategy. Although the proteins purified 
were clean of other contaminating proteins, a major setback was the final elution volume of 
the column. The strong binding interaction between biotin and avidin would require a strong 
dissociation	to	release	the	captured	proteins.	In	order	 to	elute	 the	captured	proteins	a	 longer	
elution step was necessary. This resulted in lower concentrations of protein with the need to 
concentrate the protein after purification. As the purity and yield of the antigens purified using 




 Two Fab libraries of different isotypes were prepared using the pTSL vectors. A novel 
protocol was established to study the presentation efficiency of the IgD and IgG Fab antibody 
formats by selecting against Protein L coupled beads. The presentation efficiency of scFv 
is known to be superior to Fab formats [190]. Both IgD and IgG Fab formats differ by the 
formation of disulphide bonds between the heavy and light constant regions (Figure 6.1). The 
rational of using both Fab formats was to investigate if the variation would elicit a positive or 
negative impact to the presentation efficiency of Fab formats on phage surfaces. 
 A method using Protein L coupled beads with known Fab presenting phage titres 
in a serial dilution was conducted. The method was modified from the in solution affinity 
determination by Friguet [167]. The Friguet assay involves the measurement of binding 
affinity of antibodies to proteins by ELISA equilibrium titration. The main assumption is that 
equilibrium is achieved in solution without the separation of antibody-antigen complex [191]. 
Instead of a solid phase microtitre plates, Protein L was bound to magnetic beads which would 
enhance binding, reduction of non-specific binding (low signal to background ratios) and allow 
better binding equilibrium to be achieved at a shorter time with the increased surface area 
[192]. The specificity of Protein L to capture kappa light chains was exploited to capture only 
functional	Fab	presenting	phages.	This	is	important	as	formation	of	functional	Fab	constructs	is	
dependent on the successful fusion of the light and heavy chain to form a disulphide bond. This 
method will ensure that non-fully formed Fab or wild type pIII phages are not captured to lower 
background. The determination of efficiency is based on the phage titre recovered by the beads 
after	infection.	
 Based on the protocol established, IgG Fab showed better presentation efficiency than 
IgD Fab. Therefore, the differences of the disulphide bond formation between the IgD Fab 
and IgG Fab does influence the presentation efficiency. This could be due to the structural fold 
of both Fab formats as the positions of the cysteine in IgD could be harder to access than the 
IgG.      
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6.5	 Diversity	Visualization	by	Endonuclease	(DiVE)	assay
 A rapid and cost effective method was described to monitor the distribution of diversity 
throughout the panning rounds during a phage display selection process. The basis of the 
assay is on the reannealing kinetics of double strand DNA after denaturation. The reannealing 
of single strand DNA from a pool of diverse sequences would yield multiple combinations. 
The single strand sensitivity of the S1 nuclease was used to remove any formation of nicks, 
heteroduplex loops and single stranded ends from the reannealing process. The stabilization of 
DNA duplex is a multi-factorial process which includes base sequences, concentration, length, 
thermodynamics, salt concentration and pH [193,194,195], therefore, several steps to optimize 
the S1 nuclease digestion was investigated.
Optimization of SI nuclease digestion conditions
 In this report, the basic parameters (incubation temperature, enzyme units and incubation 
time) were investigated first to optimize the S1 nuclease digestion. From the optimizations, the 
ideal temperature used was 60°C. This is within the reported optimal temperature for single-
strand-specific nuclease at 37 – 70°C [196] with a two- and three-fold increase in activity on 
single strand DNA at 45°C and 60°C respectively [170]. An optimal temperature suitable to allow 
maximum enzyme activity and ds-DNA stability is preferred. The higher temperatures were not 
suitable as they could destabilize the double strand as it nears the melting temperature. 
The second factor investigated was the amount of enzyme units required to obtain a visible band 
on the agarose gel. The reaction buffer at a final concentration of 0.5x (100 mM NaCH
3
COO, 
0.75 M NaCl, 5mM ZnSO
4
) is sufficient. The presence of Zn2+	ions	in	the	buffer	is	critical	as	
Zn2+ ions are important co-factors for the Aspergillus Orzae S1 nuclease [196]. The enzyme 
works best at high salt concentrations but as the goal is to ensure sufficient removal of ssDNA 
tails and ssDNA breaks in dsDNA, moderate conditions are sufficient for use. 
 The amount of enzyme used was titrated with 30 min incubation at 60°C. The range of 
enzyme between 0.02 U and 0.1 U was the best. As the incubation time used was 30 min this 
would then result in an assay well above 1 hr to complete. Therefore to achieve the goal of a 
rapid assay, a compromise between enzyme units and shorter incubation time was investigated. 
A concentration in between the optimized range of 0.02 U and 0.1 U was used. 3 time points 
of 10 min variations was used with 0.04 U of enzyme. By reducing the incubation times and 
moderately using the enzyme, the band intensity patterns were varied to illustrate the best
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conditions for our use. An incubation time of 10 to 20 min was sufficient to distinguish the 
variation in diversity of each panning round. 
Application of the DiVE Assay
 The concentration of DNA used was fixed at 350 ng in 50 µL (7 µg/mL) to allow easy 
handling for gel electrophoresis. The optimized protocol was applied to two different selections 
for both heavy and light chain amplicons where a positive and negative enrichment was 
observed on polyclonal level. This was to examine the durability of the protocol on amplicons 
with different sequences but of similar length. The assay proved its flexibility to adapt to both 
heavy and light chain amplicons successfully to monitor the diversity. 
 The S1 nuclease functions as a endo-exonuclease which produces 5’-mono-nucleotides 
as the end products of DNA and RNA hydrolysis [170]. Partial length fragments were observed 
resulting from the removal of ssDNA extensions from partial annealing of non-matching strands. 
The regions with the lower diversity would pose a higher change of surviving because of better 
re-annealing opportunities. This is evident with the side product bands of 173 bp and 282 bp 
from the heavy chain and light chain amplicons respectively. In general, the lower allowed 
diversity of the CDR regions would allow better chances of matching ssDNA annealing to yield 
dsDNA. This is in agreement with the diversity pattern allowed by the semi-synthetic scFv 
library used.
 The ability of this protocol to generate the diversity variation pattern for both heavy 
and light chain reinforces the robustness of the DiVE assay. Selection technologies such as 
SELEX, yeast display, ribosome display and phage display which incorporates a set of diverse 
oligonucleotides could potentially benefit from the DiVE assay. All that would be required is 
a	PCR	amplicon	generated	 from	a	 fraction	of	 the	selection	 rounds	 to	observe	 the	pattern	of	
enrichment. As selections of varying targets would perform differently, over-panning could 
result in the loss of a desired clone to those that exhibit a growth or codon usage preference. 
Hence this protocol could assist in deciding how many rounds of selection are truly required 
to generate a concentrated pool with sufficient monospecificity for the researchers’ use. In 
conclusion, this protocol can be used as a yardstick to monitor the individual diversity of each 
selection round. The DiVE assay offers a rapid, cost effective and robust method to monitor 
diversity of selection rounds from oligonucleotide libraries.
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6.6	 Phage	display	selection	with	semi-synthetic	libraries
 Phage display panning procedure was carried out using a magnetic particle processor to 
ease the workload of screening 3 libraries with 14 antigens simultaneously. This semi-automated 
high-throughput selection process was according to the method by Konthur et al. [149]. The 
protocol was initially designed for use with scFv libraries but considerations to the stringency 
of the selection were taken into account to allow a simultaneous selection of both scFv and 
Fab libraries. The stringency of each round was increased with the addition of a single round 
of wash step with every selection round. The wash times for each wash step remained constant 
and the wash buffer used was PBS-T throughout, without the addition of any denaturants, 
organic solvents, increase of temperature or counter selection target. This is to allow the mildest 
selection condition to facilitate the Fab library selections without compromising specificity or 
selectivity. An array of high, medium and low expressing antigens was used in the selection to 
simulate varying amounts of antigen concentrations used. 
 The selection process was carried out using both monovalent display and multivalent 
display. Multivalent phage display allows the presentation of multiple copies of the antibody 
fragment per phage virion, whereas monovalent display allows the presentation of maximally 
one antibody copy per phage. A complication with multivalent display was the inability to 
enrich for high affinity binders due to the avidity effect of lower affinity binders competing 
for antigen [71,84]. The use of the Hyperphage system however overcomes this problem 
[89,197]. A multivalency of the presented antibodies occurs only in the 1st	selection	round.	In	
the remaining rounds, M13KO7 is used for phage propagation. Even so, scFv and Fab formats 
have been successfully used for selection in both mono- and multivalent display systems 
[198,199,200,201].
 The panning protocol was carried out using both mono- and multivalent display for all 
three libraries in the first round and followed by monovalent display in subsequent rounds. The 
combination of multi- and monovalent display was able to enrich for all the antigens, where 
as the monovalent display approach was unable to enrich for ATX2 and GPS2. This could be 
due to the low concentrations of these two antigens in comparison to the other 11 antigens 
after purification. The success of multivalent display to enrich binders for these two antigens 
could be attributed to the avidity effect. This is in agreement with the rational of the approach 
of different display strategies at round 1 panning. The choice of either mono- or multivalent 
display is subjected to various considerations. Generally, scFv formats perform well under both
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conditions. In cases where a difficult or low concentration antigen is available, multivalent 
display for round 1 seems a more advantageous strategy.
 The selection process yielded significant enrichment for the scFv libraries and lower 
enrichment for the Fab libraries. The size of the library is believed to coincide with the affinity 
and success rate of selections against a large set of antigens [93,115]. This concept was further 
strengthened by the isolation of more than 1000 antibodies against the BLyS protein from a 
large antibody library [202]. With a larger size library, the higher number of unique clones 
will allow a higher probability to isolate binders.  This taken into account together with the 
advantage scFv formats have over the Fab constructs in terms of presentation efficiency, it is 
expected that the scFv would outperform the Fab libraries in concurrent selections[182]. This 
was evident with enrichments for all 13 antigens using the scFv library and only 2 antigens 
enriched from the IgG Fab library during the polyclonal ELISA. Majority of the enrichments 
occurred during round 3 and 4 of panning. 
 TPI-SV and UBI8 were further investigated for monoclonal selections due to positive 
enrichments in polyclonal ELISA for Fab libraries. For the first instance, soluble monoclonal 
antibody fragments were prepared by microtitre plate expression and tested on ELISA to obtain 
functional soluble antibody fragments. This was only possible for scFv formats as no signals 
were visible for both Fab libraries. There have been several strategies used to increase expression 
levels of scFv and Fab fragments by introduction of molecular chaperones, employing various 
leader peptides and varying expression protocols [203,204,205,206]. Although no signals were 
seen for Fab library monoclones, it does not necessary mean that there are no binding clones. 
This is because there is a balance that has to be achieved between functional soluble Fab from 
phage bound Fabs. Not all phage clones displaying Fab can produce Fab efficiently in bacteria 
due to the differences in folding because of the varying amino acid sequences [207]. Although 
the framework used in the library is a synthetic framework, the CDR regions still allow much 
variation which could influence the ability to express a certain Fab. Therefore to overcome 
this, phage-Fabs are used for monoclonal selection [159]. Upon the change from soluble Fab 
expression to phage-Fab expression format, positive clones were visible for both antigens. To 
ascertain the possibility that due to the difficulty in enriching polyclonal phage-Fabs, monoclonal 
selections of negative enrichment from SH3GL1, SH3GL2 and SH3GL3 antigens were also 
carried out. The notion for this experiment was to investigate the possibility of positive clones 
being present but clouded by the non-binding clones in a polyclonal pool even after panning. 
This was taken into consideration as the semi-automated protocol used was not optimized for
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a given antigen or antibody format but more of a general protocol to reduce the diversity and 
provide a more focused pool of binders. Monoclonal selections of round 4 monoclones from the 
negative enrichments were carried out for both Fab libraries. Several monoclones were found 
for SH3GL2 and SH3GL3. 
 The library panning using the semi-automated fashion could still be used with more 
success for Fab libraries with some optimizations for a less stringent selection condition. 
A series of optimization protocols could be carried out to improve the success rate of high-
throughput panning of Fab libraries. Different selection strategies have been shown to yield 
different recovery results with the same library [208]. Another consideration is that in nature, 
the light chain preference of soluble IgD is about 87% lambda [209]. The kappa to lambda 
ratio normally reflects the ratio of the most abundant Ig family in serum, usually IgG reported 
at 1.5 to 2.0 [210,211]. The preference of IgD for lambda light chain might be an indication to 
stability for the IgD protein in soluble form, therefore the use of a kappa chain in the library 
may not be the best choice.
6.7	 Format	switching
 The common formats used for antibody phage display is either scFv or Fab fragments 
[92]. The choice of format for antibody libraries depends a lot on the downstream applications. 
As it is costly to generate multiple antibody libraries of different formats, an ideal solution 
would be to generate a library using a format with the most flexibility for format switching. 
All three constructs (scFv, IgG Fab and IgD Fab) studied, generally has the same Fv regions 
grafted into the main framework. The major variation of the scFv to the Fabs is the presence of 
a peptide linker normally between 15 to 20 peptides in length [51,212]. Variations in peptide 
linkers is of huge interest as it can be used to create variations of scFv modules with different 
sizes, flexibility and valency [213,214,215]. The IgD and IgG Fab fragments differ by the 
position of the cysteine in the CH1 region resulting in a different disulphide bond formation. 
Here inter-changing of formats was carried out to observe the influence of format variations 
of similar grafted Fv region on binding characteristics. The idea is to identify the best format 
to be employed for phage display antibody library generation in the context of maintaining 




antibody formats. The binding regions of antibodies are isolated to the CDR regions where, 
in vivo somatic hypermutation occurs to increase affinity of the antibodies. Representation 
of somatic hypermutation regions of antibodies suggest a binding pocket where diversity to 
regions around the periphery of the binding site contributes to the diversity and affinity of 
the antibody to the antigen [130]. The contribution of each heavy and light chain to antigen 
binding is a highly debatable enigma. There are reports suggesting that the heavy or light chain 
contributes to antigen binding regardless of the other [216,217]. But it has also been shown that 
the relationship between both heavy and light chain is critical for antigen binding [218]. It is most 
likely that all reported influences of the heavy and light chain is true depending on the antibody 
binding regions as not all residues in the CDR but also some conserved residues actually have 
contact with the antigen [130]. The CH1-CL and VH-VL pairing functions as an ideal connector 
for one another, resulting in an increase in apparent affinity and stability [219]. Failures to 
detect a signal with Fab fragments after scFv-to-Fab conversion have been suggested to be due 
to multimerisation of medium affinity scFv that led to a strong but multivalent binding. But the 
corresponding Fab cloned remained purely monomeric hence having a lower avidity effect. 
Another reason is the alteration to the conformation of the binding pocket by the change of 
format due to the removal of the VH–VL linker sequence of the scFv [139]. The fold generated 
by the peptide linker of scFv could vary from the fold generated by the constant regions of the 
daughter Fab hence disrupting the initial epicentre for binding. This will then lead to a loss in 
the	binding	aptitude.
Conversion of scFv to Fab
 From the 4 scFv clones tested, only 1 clone (Clone 2F) exhibited high binding 
characteristics when converted to IgG Fab. This could be attributed to the amino acid sequence 
which could allow a favourable fold that still maintains the binding characteristics. IgG sub-
clones of 10D, 9A and 2C exhibited significantly lower OD readings from their respective 
parental scFv clones. On the other hand, the conversion of scFv to IgD Fab formats showed a 
decrease of OD readings similar to that of IgG Fab. IgG Fab conversions from scFv have been 
shown to have a 76% success rate in maintaining the binding characteristics to the parental 
scFv [139]. Nothing is known about IgD Fab conversions as not much has been done using 
IgD constructs but the generation of scFv libraries using IgD repertoires [109,188,189,]. The 
conversion to daughter scFv and IgD Fab clones from a parental IgG Fab clone has mixed results. 
In general, scFv formats still demonstrate good binding characteristics when converted from
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IgG Fab but a drop in binding characteristics in IgD Fab. One cannot discount the presentation 
efficiency for the drop in binding as IgD Fab was shown to have a lower presentation efficiency 
of about 8 fold in comparison to IgG Fab. The presentation efficiency of scFv is better than Fab 
due to the smaller size and mono-chain peptide construction thus allowing easier expression 
[115].
Conversion of Fab to scFv
 IgG Fab conversions to scFv have been reported to show a 10 fold decrease in affinity but 
in some cases a higher affinity is seen [220, 221]. IgG Fab conversions to scFv for both antigens 
showed slight reduction in binding (less than 10% in OD intensities). The two daughter IgD 
Fab clones from IgG 1A and IgG 5D showed different binding characteristics after conversion. 
IgG 1A had a huge drop in OD readings and IgG 5D only showed a slight drop. The huge drop 
in signal does not necessary mean a huge loss of binding but could be due to the presentation 
efficiency of IgD on phage. As determined earlier, the presentation efficiency of IgD Fab on 
phages is much lower than IgG Fab. Lower presentation efficiency would directly result in a 
lower OD reading for IgD Fab. Conversion of  IgD Fab parental clones showed a decrease in 
binding nature. As the selection was not very good for IgD Fab libraries, only one IgD Fab 
clone was used for format switching. The IgD clone when converted to IgG Fab only exhibited 
a small loss in OD readings but a bigger drop in OD when converted to scFv. This could be 
possible as IgD Fab and IgG Fab are rather similar in structure [222]. The higher loss in binding 
for scFv formats can be attributed to the distortion of the binding pocket generated by the linker 
as scFv fragments generally have a  higher presentation efficiencies than Fab constructs. 
Antibody format for library generation
 The main considerations for the ideal format to be used for antibody library generation 
would require flexibility in format conversions and good presentation efficiency. In terms of 
presentation efficiency, IgD Fab format was poorer than IgG Fab. The presentation efficiency 
of	scFv	formats	is	much	better	 than	Fab	formats	in	general	hence	giving	scFv	an	advantage	
during in vitro selections. IgD Fab conversions to scFv and IgG Fab exhibited drops in 
binding characteristics. This is to be expected during format switching. But the loss of binding 
characteristics when converted to Fab format from scFv is much higher than that for IgG Fab to 
scFv. The drop of binding from IgD Fab to IgG Fab is much higher than conversions in reverse. 
Overall, IgG Fab format appears to be the ideal choice of format for antibody library generation.
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The versatility of the IgG Fab in format conversions in comparison to scFv and IgD is the best 
with minimal loss of binding characteristics when converted to scFv and IgD in comparison to 
the	reverse	conversion	orders.	
 It was observed from the performance of the parental and daughter antibodies that the 
selected monoclonals perform best in the format they were selected in originally. Any form 
of conversion will undoubtedly lower the binding characteristics either in terms of affinity 
or avidity which can be detrimental for downstream applications. A compromise between 
presentation efficiency and format conversion compatibility would mean IgG Fab is the most 
ideal format to be used for library generation.
6.8	 V-gene	primer	design,	analysis	and	repertoire	generation	from	B-cells
 To obtain V-gene repertoires from a pool of B-cells, an optimized protocol to generate a 
IgG Fab antibody library would be required. A series of protocols ranging from V-gene primer 
design, cDNA synthesis and V-gene amplification was investigated.
Bioinformatic analysis of V-gene primers
Most human V-gene specific primers applied to date are based on the germ-line sequences 
present in VBASE [223], a manually compiled database of all known human immunoglobulin 
V-genes at the time, which was developed more than a decade ago at the MRC Centre for 
Protein Engineering in Cambridge UK (REFs). In 1998, Sblattero and Bradbury compiled a 
minimal set of primers for V-gene amplification [171] which was used as a basis for the study. 
Here, all primer were analysed using the collection of available V-gene sequences from the 
VBASE2 [173]. This database is regularly updated, it incorporates sequence information from 
genome sequencing projects included in EMBL-Bank/GenBank/DDBJ [224] and Ensembl 
[225] as well as additionally integrates the information of existing immunoglobulin sequence 
databases such as VBASE, the last version of publicly available Kabat database [226] or the 
IMGT/LIGM database [227, 228]. Detailed primer analysis using all 576 available entries 
from VBASE2 suggests, that by designing primers using reference sequences (family assigned 
genes) the coverage For all heavy and lambda V-genes excluding pseudogenes and orphans is 
in the region of 99 % and 97 %, respectively. The lower coverage of the kappa V-genes at 92 
%is due to gene sequences with insertions or deletions compared to the primer sequence, which 
resulted in too many mismatches and consequently did not meet the stringent criteria set for the
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analysis parameters. For this reason, new primers were suggested: two primers for nine light 
kappa chain genes, a primer for three light lambda chain genes and a primer for the single 
non-covered functional gene (heavy chain). They were designed in order to increase the total 
coverage up to 97 %, but this is also an opportunity to check if the additionally covered genes 
are used in the V(D)J recombination, since only genomic references are available up to date. At 
present, no such V-genes could be analyzed as the primers used do not amplify those V-genes. 
The introduction of the new primers to the existing primer set would greatly improve  the 
coverage. In essence, the primer set used in this protocol does give a diverse coverage for the 
respective	families	based	on	the	current	gene	information	available.	Thus	the	primer	set	is	able	
to cover the entire antibody repertoire with a confident coverage of V-genes.
Influence of different enzymes
 cDNA synthesis from total RNA is a decisive measure in obtaining cDNA material for 
gene expression analysis. The decision on which priming method is critical as it will determine 
the outcome. The RT should reflect the true messenger RNA (mRNA) population for the 
transcript of interest. Conventional protocols require the synthesis of the first strand cDNA using 
MMLV reverse transcriptase that lacks RNase H activity [229]. In this study,  SuperScript® 
II and totalscript-OLS® reverse transcriptases was evaluated for both, V-gene -specific and 
total cDNA synthesis. A previous comparison of the RTases showed that although conversion 
of RNA to cDNA of abundant transcript is equally efficient, the same did not apply for low 
abundance transcripts. SuperScript II has been shown to be more efficient with low transcript 
genes [230]. This is fully in concordance with our findings. IgD-specific transcripts are low 
abundant in RNA samples of PBMCs and only weak signals are obtained from the totalscript-
OLS oligo(dT) cDNA as template compared to SuperScript II converted RNA. However, 
the addition of ET SSB to the PCR reaction mixture greatly enhances the PCR efficiency of 
totalscript-OLS cDNA. A fine balance of the amount of RNA used for RT reaction is important. 
When high amounts of RNA are used for RT, RTase could cause an overamplification of certain 
transcripts at certain PCR conditions, leading to misrepresentation of individual transcript 
populations [231]. A sensible ratio of RTase to RNA template should be preserved because a 
high ratio of RTase to RNA template could lead to polymerase inhibition [232]. We used 400 
ng total RNA for every RT reaction. This is well within the recommended amount of RNA 
for use, and indeed, we saw neither signs of PCR inhibition nor false amplification. While 
both RTases tested, SuperScript II and totalscript-OLS, gave comparable results when used 
with gene-specific primers, SuperScript II had however an advantage when used with generic 
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oligo(dT) priming in having a consistently higher yield. For the synthesis of cDNA for V-gene 
amplification, hence, SuperScript II seems the ideal choice with ample yield and specificity. 
IgD-specific cDNA was synthesized with an anti-sense primer in the IgD hinge region which is 
unique over the hinge regions of other isotypes. The specificity of the cDNA synthesized from 
IgD-specific primer did not show cross reaction with IgG isotype primers. The amplification 
using IgG CH1 specific primers was not able to show any amplification leaving no doubt to 
the sensitivity of the primer used for cDNA synthesis. The control samples being the cDNA 
derived from oligo(dT) and random hexamer priming was able to demonstrate the success of 
the RT-PCR process. The oligo(dT) sample confirmed the amplification of the IgG fragment 
with the expected band size. The choice to use either gene-specific primers, oligo(dT), random 
hexamers or a combination of oligo(dT) and random hexamers (in our case) for priming is a 
delicate issue. RT efficiency depends on the priming strategy while the yield is dependent on 
the RNA concentration [233]. Specific primer priming rather than random priming has been 
reported to show an increase in sensitivity [234]. This is important in low transcript gene cDNA 
synthesis. 
 There are several commercially available polymerases in the market today. The choice of 
a polymerase, which is optimal for the application at hand, is an enigma in most cases. Therefore, 
a comparison of the performance was carried out for the three different polymerases (REDTaq, 
BIO-X-ACT and Phusion) in respect to V-gene amplification efficiency, which is the most 
important parameter as it determines the PCR product yield. Several other factors such as target 
length and sequence, primer design, buffer conditions, sample impurities, cycling conditions 
and polymerases can influence the amplification efficiency [235,236]. The recommended 
buffers were applied to minimize variations for an optimal condition. Additionally, the supplier 
recommended units of polymerases was also used. In the comparison, all three polymerases 
could be used for the amplification with partially only poor to moderate yield.
Effects of additives
 Additives are occasionally used in PCR reactions to increase the amplification efficiency. 
Hence, a MgCl2 concentration optimization was carried out by adding three different MgCl2	
concentrations (0.25 mM, 0.5 mM and 1.0 mM) to the manufacturer supplied standard buffers, 
which already contained between 1.0 mM to 1.5 mM MgCl2. Some improvement in amplification 
was visible for REDTaq and BIO-X-ACT in comparison to the respective standard MgCl2	
concentrations, while performance of Phusion remained consistent throughout the range. 
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It is concluded that Phusion gives the best yield using standard conditions without any MgCl2	
optimization and hence may be the enzyme of choice to amplify all antibody isotype and 
idiotypes using the same PCR program for all primer pairs in a single run. 
	 Further	 optimisation	 investigated	 the	 use	 of	 additives	 in	 the	 PCR	 reaction	mixture.	
Addition of DMSO to reduce DNA secondary structures led to no improvement and therefore 
the influence of a thermostable singe strand binding protein on the PCR reaction was assessed. 
SSB proteins destabilize DNA-complexes in vivo to allow higher accessibility to single 
stranded DNA. It enhances the fidelity of DNA synthesis, processivity of polymerases and 
promotes polymerase binding [237]. This allows better primer binding to single stranded DNA 
and augment PCR amplification. With both, gene-specific and oligo(dT) cDNA amplification 
in the presence of ET SSB, a marked increase in yield for both single and pooled primer 
amplifications was seen. Also, comparable efficiency between both single primer and primer 
pool amplification was visible with ET SSB. The availability of ET SSB would allow better 
functionality of multiplex PCR platforms and increased specificity as well as efficiency of 
conventional PCR. This was evident with the overall higher amplification pattern of both gene-
specific and oligo(dT) of ET SSB treated samples to that without. The effects on the cDNA 
derived from different RTase were also recorded. Without ET SSB, SuperScript II oligo(dT) 
derived cDNA showed a major advantage over Totalscript-OLS. With the addition of ET SSB, 
oligo(dT) derived cDNA for both SuperScript II and Totalscript-OLS was now comparable. The 
presence of ET SSB assisted the amplification of oligo(dT) derived cDNA from Totalscript-
OLS.
 It is seen that the use of ET SSB is beneficial for V-gene amplifications and should be 
adopted when amplifying diverse sets of antibody sequences from cDNA in multiplexed and 
single PCR reactions equally. 
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Evaluation of optimised protocol
 The optimised protocol for amplifying V-genes of various idiotypes to the IgD, IgG, 
kappa and lambda isotype was assessed. The procedure including all primer combinations 
worked to satisfaction and produced significant yield of DNA amplification. The variation 
seen in band intensities for the antibody profiles is due to the V-gene usage preferences. This 
preference is attributed to the high diversity in antibody repertoires. The diversity is credited 
to the antibody V-gene recombination processes [238] including receptor editing and somatic 
hypermutation [239]. This is important as antibodies of similar V-gene sequence but of different 
isotypes have demonstrated differences in specificity and idiotype [240]. Therefore, being able 
to amplify an array of multiple isotypes and idiotypes would be convenient for such studies. 
Studies on V-gene usage patterns have also been of interest to understand if a certain idiotype 
or isotype is preferred, which could be related to the cause of a certain condition. Hence the 
protocol could contribute to current V-gene usage studies conducted for various diseases such as 
systemic lupus erythematosus [241,242], Sjögren disease [243], rheumatoid arthritis [244,245] 
and even leukaemia [246]. The ability to amplify a significant amount of cDNA of V-genes from 
various antibody isotype and idiotype could also have an advantage in recombinant antibody 
library generations [247,248,249]. From the entire profile of the antibody isotype and idiotype 
amplification, the presence of some non-specific bands was noticed to being amplified. Even 
so, those bands are distinctive in size to allow correct excision of the required antibody V-gene 
bands	from	an	agarose	gel.
 In conclusion, an optimised procedure for human antibody isotype and idiotype 
amplification was set up by revisiting all relevant steps for V-gene amplification in detail. The 
work included optimisation of amplification primers, assessment of reverse transcriptases for 
cDNA synthesis as well as evaluation of polymerases and additives for PCR amplification. 
Furthermore, the method is able to produce Ig-isotype specific cDNAs for idiotype amplification. 
Therefore, it is proposed that by designing specific reverse primers the protocol can be adapted 
to amplify other isotypes such as IgA, IgE and IgM with their respective idiotypes.
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Optimization of V-gene repertoire for library generation
	
 With the optimized protocol, it would be possible to generate V-gene repertoires of a 
high diversity as templates for antibody library generation. However, the amplification of each 
V-gene family from a pool of individuals would require numerous rounds of amplification. 
In this work, the influence of pooling donor cDNAs for amplification was investigated with 
hopes to minimize the number of amplification required without sacrificing the diversity of 
the V-genes. As each individual exhibits different V-gene usage, a set of five individual V-gene 
profiles was generated for comparisons to a pool of the five donor cDNAs. Equal amounts of 
cDNA from each individual was pooled and amplified with the established method. The V-gene 
repertoire from the pool cDNA corresponds to the individual profiles thus ensuring no lost of 
diversity or preferences during amplification. Therefore, a pool of 5 individual cDNA at equal 
amounts can be used to amplify V-gene repertoires for antibody library generation without any 
loss in diversity. By applying the established protocol for V-gene amplification and pooling 5 
donors together, this could facilitate the generation of a human antibody library with a high 




types	of	 entities	deemed	 foreign	by	 the	body	 is	down	 to	 the	huge	diversity	of	 the	antibody	










	 The	 aim	 of	 the	 thesis	 was	 to	 investigate	 different	 parameters	 that	 contribute	 to	 the	




another.	The	use	of	 ccdB	gene	 cassettes	 in	 the	 cloning	 sites	 allows	 low	background	during	
initial	library	cloning.
	 To	 investigate	 the	 influence	of	different	antibody	scaffolds	on	display	efficiency	and	
antibody	panning,	a	human	semi	synthetic	scFv	antibody	library	was	subcloned	into	IgD	and	
IgG	Fab	format	 rather	 than	generating	a	completely	naïve	 library	of	Fab	formats.	This	 is	 to	




terms	of	both	Fab	 formats	evaluated,	 IgG	Fab	performed	better	 than	 IgD	Fab	with	a	8-fold	
presentation	efficiency.
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	 A	 novel	 method	 was	 designed	 to	 monitor	 the	 distribution	 of	 diversity	 throughout	
the	 pannings	 rounds	 of	 a	 phage	 display	 selection.	 The	 DiVE	 (Diversity	 Visualisation	 by	










or	 low	 concentration	 antigen	 is	 available,	 multivalent	 display	 for	 round	 1	 appears	 a	 more	
advantageous	strategy.
	 Next,	 the	 interchange	 of	V-regions	 between	 individual	 formats	 and	 the	 influence	 on	
binding	characteristics	was	 evaluated.	From	 the	 format	 conversion	experiments,	 in	between	
three	formats	-	scFv,	IgD	Fab	and	IgG	Fab	-	IgG	Fab	was	the	best	format	as	it	showed	the	lowest	
drop	in	binding	characteristics	when	converted	to	the	either	scFv	or	IgD	Fab.
	 Once	 the	 best	 interchangeable	 format	 for	 antibody	 library	 design	 was	 determined,	
the	amplification	procedure	to	generate	an	IgG	Fab	library	from	human	donor	materials	was	
assessed.	First,	a	set	of	V-gene	primers	was	designed	and	evaluated.	The	primer	set	was	analyzed	














synthesis	 from	 total	RNA	extracts	of	peripheral	blood	mononuclear	cells	and	ultimately	 the	
polymerase	chain	reaction	(PCR).	





MgCl2	 did	 not	 affect	 the	 outcome.	 To	 further	 improve	 the	 amplification,	 the	 addition	 of	 a
single-strand	binding	protein	(ET	SSB)	was	evaluated.	It	was	found	that	ET	SSB	is	beneficial	
for	V-gene	 amplifications	 and	 should	 be	 adopted	when	 amplifying	 diverse	 sets	 of	 antibody	






protocol,	 it	 provides	 the	 user	 a	 rapid,	 specific	 and	 efficient	method	 to	 generate	 preparatory	
materials	for	library	generation.	The	pTSL	phagemid	vector	series	constructed	supplements	the	
production	of	antibody	libraries	for	phage	display	with	the	possibility	of	switching	in	between	






	 This	work	offers	 the	possibility	 to	 support	 future	 studies	 in	V-gene	usage	 studies	en	
route	to	understanding	the	mechanisms	of	immunological	based	diseases	such	as	autoimmunity.	



















umfasst.	Die	Diversität	 des	menschlichen	Antikörper-Inventars	wird	 durch	 kombinatorische	
Auswahl	 verschiedener	 DNA-Segmente,	 die	 für	 Antikörper	 codieren,	 bewerkstelligt	 [92].
In	 Hinblick	 auf	 das	 prospektive	 Potenzial	 von	 Antikörpern	 in	 Therapie	 und	 Diagnostik	
wurden	effektivere	und	effizientere	Strategien	untersucht,	die	zur	Verbesserung	der	 in	vitro-
Erzeugung	menschlicher	Antikörper	führen	sollen.	Allerdings	erweist	sich	auch	der	in	vitro-
Herstellungsprozess	 humaner	 Antkörper	 als	 	 komplizierter	 und	 mehrstufiger	 solcher.	 Die	
Qualität	von	Antikörper-Bibliotheken	wird	von	verschiedenen	Faktoren	beeinflusst,	darunter	
Antikörperformate,	 “display	 level”,	 Sequenzdiversität,	 Expressionsstärke,	 Tendenz	 zur	








sind.	Außerdem	 erlauben	 diese	 Vektoren	 das	 “shuttleing”	 von	Antikörpergenen	 von	 einem	
Format	 in	 ein	 anderes.	Die	Verwendung	von	CcdB	Genkassetten	 an	den	Klonierungsstellen	
ermöglicht	einein	geringen	Hintergrund	während	des	initalne	Bibliotheksklonierung.
	 Um	 den	 Einfluss	 verschiedener	 Antikörpergerüste	 auf	 die	 Effizienz	 des	 Displays	











über	 die	 einzelnen	 Panning-Runden	 einer	 Phage-Display-Selektion	 zu	 verfolgen.	 Der	
DiVE	 (Diversity	 Visualisation	 by	 Endonuclease)	 Assay	 verbindet	 Reannealing-Kinetik	







verschiedener	 Antigene	 und	 Bibliotheken	 zu	 gestatten.	 Aus	 beiden	 Bbliotheken	 wurden	
spezifisch	 bindende	 Antikörperfragmente	 isoliert.	 Der	 Selektionsprozess	 wurde	 mittels	
zweier	 verschiedener	 Wege	 durchgeführt,	 einer	 monovalenten	 und	 einer	 polyvalenten	
Display-Strategie.	Die	Beobachtung	 zeigte,	 dass	 in	 Fällen	 schwieriger	 oder	 nur	 in	 geringer	
Konzentration	verfügbarer	Antigene,	die	multivalente	Display-Strategie	für	die	erste	Runde	der	
vielversprechendere	Ansatz	zu	sein	scheint.
	 Im	 nächsten	 Schritt	 wurde	 der	 Austausch	 von	 V-Regionen	 zwischen	 individuellen	




	 Nachdem	 das	 beste	Austauschformat	 für	 das	Antikörper	 Bibliotheksdesign	 ermittelt	




Abdeckung	 der	 bekannten	V-Gen-Sequenzen	 gewährleisten.	 Basierend	 auf	 der	 spezifischen	











ist,	 stellt	 auch	 ein	 optimiertes	 Amplifikationsprotokoll	 eine	 unabdingbare	 Voraussetzung	
dar,	 denn	 beides	 muss	 Hand	 in	 Hand	 zusammen	 wirken,	 um	 den	 Erfolg	 sicherzustellen.	




	 Zwei	 RTasen	 zur	 cDNA-Präparation	 unterschiedlicher	 Herkunft	 wurden	 untersucht.	
SuperScript	II	RTase	zeigte	bessere	Leistung	als	der	Mitbewerber	in	Hinblick	auf	die	Ausbeute	
sowohl	 bei	 genspezifischem	 als	 auch	 generischem	 oligo(dT)-Priming.	 Einige	 kommerziell	
verfügbare	 Polymerasen	 (REDTaq,	 BIO-X-ACT	 und	 Phusion)	 wurden	 in	 Hinblick	 auf	 die	
V-Gen-Amplifikation	analysiert.	Dabei	zeigt	die	Phusion	die	konsistenteste	Leistung	mit	der	
gesamten	Auswahl	 an	 verwendeten	V-Gen-Primern.	Zusätze	wie	DMSO	und	MgCl2	 hatten	
keinen	Einfluss	auf	das	Resultat.	Um	die	Amplifikation	weiter	zu	verbessern,	wurde	der	Zusatz	
von	 Einzelstrang-Bindungsprotein	 (ET	 SSB)	 untersucht.	 Es	 hat	 sich	 gezeigt,	 dass	 Zugabe	










erreicht	 werden	 kann.	 Im	 Zusammenspiel	 mit	 dem	 optimierten	 Protokoll	 stellt	 sie	 dem	
Benutzer	 eine	 schnelle,	 spezifische	 und	 effiziente	Methode	 zur	 Verfügung,	 um	 präparative	









basierter	 Krankheiten	 wie	 etwa	 Autoimmunerkrankungen.	 Solche	 Studen	 dürften	 vom	
vorliegenden	 optimierten	 Protokoll	 sowie	 der	 erhöhten	 Abdeckung	 profitieren.	 Während	
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Ab   Antibody
ABTS   2,2’-azino-bis (3-ethylbenzthiazoline 6-sulfonic acid) diammonium
Amp  Ampicillin
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bp   Base pair
BSA   Bovine serum albumin
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Cam  Chloramphenicol
cDNA   Complementary DNA
CDR   Complementarity determining region
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CSR  Class switch recombination
C-terminus  Carboxy-terminus
D.
Da   Dalton
ddH2O  Double distilled water
DNA   Deoxyribonucleic acid
dNTP’s  Deoxyribonucleosid-5’-triphosphate
dsDNA  Double stranded DNA
D segment Diversity segment
DTT   Dithiothreitol
E.
E. coli   Escherichia coli
EDTA   Ethylendiaminotetraacetic acid
ELISA		 Enzyme-linked	immunosorbent	assay
F.
Fab   Fragment antigen binding
FACS   Fluorescence assisted cell sorting
Fc   Fragment crystalline
Fv   Variable fragment
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G.
Glu   Glucose
H.
HACA  Human-anti-chimeric response
HAMA  Human-anti-mouse response




HRP   Horseradish peroxidase
I.






IG region  Intergenic region
IgV  Immunoglobulin variable domain
IMAC			 Immobilised	metal	affinity	chromatography
IPTG   Isopropyl-ß-D-thiogalactoside
J.









mAb   monoclonal Antibody





mRNA  Messenger RNA
MPP  Magnetic particle processor
MTP   Microtitre plate
MW   Molecular weight (in Dalton)
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N.




OD   Optical Density
OD600   OD at 600 nm wavelength
o/n	 	 Over	night
P.
pI-pXI  Phage proteins I to XI.
PAGE   Polyacrylamide gel-electrophoresis
PBS   Phosphate buffered saline
PBS-T  Phosphate buffered saline with Tween 20
PBMC  Peripheral blood mononuclear cells
PCR   Polymerase chain reaction
PEG   Polyethylene glycol






RNA   Ribonucleic acid
rt  Room temperature
RT   Reverse transcriptase
rpm  Revolutions per minute
S.
scFv   Single chain variable fragment
scFab  Single chain fragment antigen binding
SDS   Sodium dodecylsulfate
sec  Seconds
SSB   Single-strand DNA binding protein
ssDNA  Single stranded DNA
SHM  Somatic hypermutation
T.
Taq   DNA polymerase from Thermus aquaticus
TEMED  N,N,N’,N’-tetramethylethylenediamine
Tris   Tris(hydroxymethyl)-aminomethane
tRNA   transfer RNA
Tween 20  Polyoxyethylenesorbitan monolaurate
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U.
U  Enyzme units
V.
V   Volt
V-genes Variable genes
VH   Variable domain of the immunoglobulin heavy chain
VL		 	 Variable	domain	of	the	immunoglobulin	light	chain
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4.            123
182
Figure 5.1:  PCR amplicon of IgD CH1 fragment.     123
Figure 5.2:  PCR amplicon of the ccdB cassete for heavy and light chain region. 123
Figure 5.3: Chronology of pTSL phagemid vector series. (A.) pTSL 1 with a dual ccdB 
cassette for scFv conversion to IgD Fab, (B.) pTSL 2 with a dual ccdB cassette for scFv 
conversion to IgG Fab, (C.) pTSL3 with a dual ccdB cassette for the generation of full Fab 
cosntructs, (D.) pTSL4 with a single ccdB cassette for cloning pIII fusion constructs. 123
Figure 5.4: ccdB activity evaluation of pTSL phagemid vector series on DB3.1 and DH10B. 
(A.) pTSL1 in DB3.1 and DH10B, (B.) pTSL2 in DB3.1 and DH10B, (C.) pTSL3 in DB3.1 
and DH10B, (D.) pTSL4 in DB3.1 and DH10B, (E.) Control plasmid pUC18 in DB3.1 and 
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Figure 5.5: PCR amplification of heavy and light variable regions.   123
Figure 5.6: PCR amplification of amplify the cloning cassette from pTSL2 using LMB and 
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Figure 5.7: NotI digestion of cloning cassette from pTSL2. (A) Cartoon showing the fragments 
of the amplified cloning cassette. (B) Gel electrophoresis separation of NotI digestion of the 
cloning cassette.          123
Figure 5.8: PCR amplification of VL ligated to cloning cassette from pTSL2. (A) Cartoon 
showing the fragments of the amplified VL-cloning cassette. (B) Gel electrophoresis separation 
of the VL-cloning cassette.         123
Figure 5.9: PCR amplification of VL ligated to cloning cassette from pTSL2. (A) Cartoon 
showing the fragments of the amplified VL-cloning cassette. (B) Gel electrophoresis separation 
of the VL-cloning cassette.         123
 
Figure 5.10: PCR amplification of VH ligated to VL-cloning cassette. (A) Cartoon showing 
the fragments of the amplified VH-VL-cloning cassette. (B) Gel electrophoresis separation of 
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sub-cloning. (A.) SalI/MluI digested pTSL2 not ligated, (B.) Religation of SalI/MluI digested 
pTSL2, (C.) Uncut pTSL2, (D.) pUC18 Control. DB3.1 cells were used on the left panel and 
DH10B cells were used on the right panel.       123
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Figure 5.13: Colony PCR analysis showing 8 of 24 selected clones. (A.) IgD Fab library 
clones, (B.) IgG Fab library clones. The remaining 16 clones from the IgD library had 1 negative 
and 15 positives. The remaning 16 clones for the IgG library were positive.  123
Figure 5.14: Distribution pattern of amino acids allowed by DVT codon at allowed positions 
in the CDR regions. (A.) Number of varying amino acids in the Variable Heavy Chain, (B.) 
Number of varying amino acids in the Variable Light Chain, (C.) Distribution pattern amino 
acid based. Red represents CDR2 and yellow for CDR3 positions where randomizations are 
allowed. Numbers represent positions. L is for the Light Chain and H is for the Heavy Chain. 
Overall represents the overall distribution of amino acids regardless of position.  132
Figure 5.15: Protein purification strategies used.  (A.) Ni-NTA (Nitrilotriacetic acid), 
(B.) Ni-TED (Tris(carboxymethyl) ethylendiamin), (C.) Monoavidin.   123
Figure 5.16: Coomassie stained SDS gel comparison of Ni-TED and Ni-NTA purification 
of proteins. (A.) Ubi8 protein with an expected size of 20 kDa, (B.) GRB2 protein with an 
expected size of 30 kDa, (C.) MAPK9 protein with an expected size of 55 kDa.  123
Figure 5.17: Silver stainned SDS gel of PARK-7 using monomeric avidin. The expected size 
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Coomassie stained SDS-PAGE analysis for expression levels, (B.) Western-Blot analysis for 
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Figure 5.20: Antibody format presentation efficiency assay for IgD Fab and IgG Fab on 
phage surface. (A.) Dilution curve of the antibody format presentation efficiency, (B.) Log 
based linear regression of the dilution curves for the antibody format presentation assay. 123
Figure 5.21: Principle of the DiVE Assay for visual evaluation of diversity from phage 
display library panning rounds. (A.) Phage panning to derive enriched pool of sequences for 
PCR amplification. (B.) Denaturation and annealing of PCR amplified fragments. Diversified 
regions are confined to CDR 2 and CDR 3. S1 nuclease will digest bubbles formed by mismatches. 
Electrophoresis to visualise diversity via variation in band intensities.    123
Figure 5.22: Optimisation of S1 nuclease digestion conditions. (A.) Incubation temperature 
variation with 1 U of S1 nuclease. (B.) Titration of S1 nuclease with 60°C incubation for 30 
minutes. (C.) Incubation time variation with 0.4 U of S1 nuclease. The samples used are PCR 
amplified fragments of the variable heavy chain region of clone 4IE3, round 2 and round 4 of 
selection. Expected band size is approximately 360 bp. + and - represents the addition of S1 
nuclease to the sample.         123
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probable fragments formed by the DiVE Assay. (A.) Variable heavy chain fragment. (B.) 
Variable light chain fragment. The samples used are PCR amplified fragments of the variable 
region of a single clone 4IE3 and various rounds of the library selection (positive and negative 
enrichment of binders). Expected band sizes are approximately 363 bp for heavy chain and 
354 bp for light chain. On the right, schematic representation of the variable sequences. CDR’s 
are represented as bubbles with the numbers indicating the frequency of varying amino acid 
positions. The 173 bp band coincides with the length of the 5’-end to 3’-end of the heavy chain 
antisense framework whereas the 282 bp band corresponds to the sense strand length of the 5’ 
end to the 3’ end of the framework before CDR3 of the light chain after S1 nuclease digestion.
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Figure 5.24: Batch sequencing of selection rounds and clone 4IE3. (A.) Variable heavy 
chain sequences. (B.) Variable light chain sequences. Sequences highlighted in red boxes are 
regions of diversification.         123
Figure 5.25: SDS-PAGE analysis of the 13 selected antigens coupled to streptavidin beads 
for antibody selection process.         132
Figure 5.26: Polyclonal ELISA results of panning rounds with the scFv, IgG Fab and 
IgD Fab libraries with two different disaply methods. M13KO7 represents library using 
the Exclusive Mono method and Hyperphage is for the Combo display method. Grey areas 
represent the background OD readings and black coloured bars represent the OD readings of 
samples.           123
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and UBI8. (A.) Results of the additional rounds including the previous rounds for TPI-SV for 
IgG Fab and IgD Fab library with both display methods, (B.) Results of the additional rounds 
including the previous rounds for UBI8 for IgG Fab and IgD Fab library with both display 
methods. Grey areas represent the background OD readings and black coloured bars represent 
the OD readings of samples.         133
Figure 5.28: Monoclonal ELISA of selected clones for TPI-SV and UBI8. (A.) Results of 
the monoclonal ELISA for TPI-SV from all libraries, (B.) Results of the monoclonal ELISA for 
UBI8 from all libraries,.Grey areas represent the background OD readings and black coloured 
bars represent the OD readings of samples. TPI-SV IgD library was screened from both M13KO7 
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Figure 5.29: Format switching in-between the three formats. The original format of the 
clone is regarded as the parental format and the subsequent conversions are termed daughter 
formats. scFv is connected by a glycine serine linker whereas IgD and IgG Fab formats are 
formed by disulphide bonds at different positions.      123
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Figure 5.30: Format switch phage ELISA of selected clones. The parental format clones are 
named at the bottom for each  subset. Each parental format was converted to the other possible 
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Figure 5.31: Comparison of reverse transcription efficiency and specificity of IgD gene 
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are: (i) REDTaq Polymerase, (ii) Bio-X-Act Polymerase and (iii) Phusion Taq Polymerase. 
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MgCl2 forward primers. All amplifications was carried out using the IgD CH1 reverse primer. 
Expected band sizes range from 650 to 700 bp. Donor template for A differs from B and C, 
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samples and ET SSB are as depicted. Primers are as follows: (a) VH Pool (b) VH 1257. 
All samples were amplified using IgD-CH1-Rv primer. Expected band sizes range from 650 
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Figure 5.34: Full antibody isotype and idiotype amplification with a single donor sample. 
Amplification was carried out using isotype specific reverse primers: (A.) IgD (IgD-CH1-Rv), 
(B.) IgG (IgG-CH1-Rv), (C.) Lambda (Pool Lambda CL1-Rv & Lambda CL2-Rv), (D.) Kappa 
(Kappa CL-Rv). Idiotype specific forward primers are as depicted. Expected band sizes range 
from 650 to 700 bp.          123
Figure 5.35: Full antibody isotype and idiotype amplification of five individual donors 
and a pool of five donor cDNAs. Amplification was carried out using isotype specific reverse 
primers: (A.) IgD (IgD-CH1-Rv), (B.) IgG (IgG-CH1-Rv), (C.) Lambda (Pool Lambda CL1-
Rv & Lambda CL2-Rv), (D.) Kappa (Kappa CL-Rv). Idiotype specific forward primers are as 
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Figure 6.1: Teriary and secondary structure of IgD Fab (PDB: 1ZVO) and IgG Fab (PDB: 
1HZH). (A.) IgD Fab, (B.) IgG Fab. The red lines represent the beginning of the CH1 region 
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